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ABSTRACT 
 
Psoriasis is the most common chronic skin inflammation in adults which affects 2-4% of the 
world population. Keratinocytes are the key structural cells in epidermis which hyper-
proliferate and undergo aberrant differentiation in psoriasis. Keratinocyte-derived cytokines 
and chemokines are essential in maintaining the vicious auto-inflammatory loop in psoriasis. 
MicroRNAs (miRNAs) are small RNAs (22-25 nucleotides) which regulates gene expression 
at the post-transcriptional level. In this thesis, we explored the functional role of miRNAs/ 
cytokine networks in psoriasis.  
Paper I: A strong protective association of SNP (rs2910164-CC) of miR-146a to early onset of 
psoriasis was observed in HLA-C*06-negative patients. In addition, miR-146a deletion in mice 
led to earlier onset, more severe inflammation and impaired healing of imiquimod-induced 
psoriasis-like skin inflammation. Therapeutically, miR-146a mimic injection prevented 
psoriasiform skin-inflammation in WT mice, suggesting an anti-inflammatory role of miR-
146a.  
Paper II: Here we explored the landscape of miRNAs in psoriatic keratinocytes. We identified 
several miRNAs, which were not identified in psoriasis before and their expression was altered 
in keratinocyte. In addition, upregulation of miR-1307-3p and human-specific miR-941 was 
validated with qRT-PCR. 
Paper III: MiR-149 was found to be downregulated in psoriatic keratinocytes compared to 
keratinocytes from non-lesional or healthy skin. In vitro studies revealed that the 
downregulation of miR-149 is mediated by IFN-γ/JAK/STAT axis. Functionally, miR-149 
targeted the inflammatory and JAK/STAT pathway genes in resting as well as in IFN-γ treated 
keratinocytes. Moreover, miR-149 inhibition potentiated IFN-γ responses in keratinocytes.  
Paper IV: Here we outlined a new mode of action of tofactinib, a JAK inhibitor with effects on 
psoriasis in clinical trials. We showed that JAK proteins that are targets of tofacitinib are 
expressed by keratinocytes and tofacitinib had a robust impact on IL-22- regulated 
transcriptome in keratinocytes. Our results imply that effects of tofacitinib are not just limited 
to T-cells as previously thought but can also be observed in keratinocytes.  
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1 BACKGROUND 
Being the largest organ of the body, skin is the first line of defence against pathogens, heat, 
chemical and toxic insults (Di Meglio et al., 2011, Nestle et al., 2009a). Often, devising an 
adequate immunological response to the insult is a great challenge; as an insufficient response 
can result in life threatening infections or tumour formation while an overwhelming response 
can result in chronic inflammation or autoimmune diseases (Di Meglio et al., 2011, Nestle et 
al., 2009a). In this thesis we made an attempt to understand the pathophysiological mechanisms 
of an inflammatory skin disease- psoriasis, focusing on miRNA-mediated gene regulation and 
cytokine signalling in keratinocytes.  
 
1.1 The skin 
The skin is constantly exposed to external provocations and microorganisms (Di Meglio et al., 
2011, Nestle et al., 2009a, Simpson et al., 2011) and forms the primary interface between the 
environment and the organism by creating physical, chemical and immunological barrier (Di 
Meglio et al., 2011, Simpson et al., 2011). Apart from synthesising vitamins (vitamin D3) 
(Holick et al., 1987) and hormones (sex hormones and insulin-like growth factor-binding 
proteins) (Zouboulis, 2000) skin also restricts water loss, resist mechanical stress, protects from 
potential assault by foreign organisms or toxic substances and act as a sensory organ (Di Meglio 
et al., 2011, Simpson et al., 2011). Human skin consist of an outer layer (epidermis), and inner 
layer (dermis) and hypodermis (Figure 1).  
 
 1.1.1 Epidermis 
The epidermal compartment is majorly composed of keratinocytes (>90%), however 
melanocytes, immune cells (Langerhans cells and T lymphocytes) and Merkel cells also reside 
in the epidermis (Figure 1) (Di Meglio et al., 2011, Nestle et al., 2009a). From the innermost 
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layer to the outermost layer, the epidermis is divided into the stratum basale, the stratum 
spinosum, the stratum granulosum and the stratum corneum (Figure 1).  
 
Figure 1: Skin anatomy and effector cells. Reproduced with permission from Nestle et al., 2009. 
Copyright Springer Nature. 
 
Keratinocytes start to differentiate as they leave the stratum basale and finally die and 
ultimately shed off from the body at stratum corneum  (Figure 1) (Simpson et al., 2011). In the 
stratum basale, keratinocytes (stem-like-cells) proliferate and divide (Figure 1) (Blanpain and 
Fuchs, 2009, Simpson et al., 2011). In the stratum spinosum, keratinocytes lose their mitotic 
activity to increase in size and form intracellular connections via gap junctions and 
desmosomes. In the stratum granulosum, keratinocytes starts to get flattened and a water 
impermeable cornified envelop underlying plasma membrane is formed (Di Meglio et al., 
2011, Simpson et al., 2011). In the stratum corneum, keratinocytes become compactly 
crosslinked to form ultimate skin barrier (Figure 1). The desquamation of the cornified layer 
of epidermis maintains the division of keratinocytes at the basal layer (Simpson et al., 2011). 
The differentiation of keratinocytes is a tightly regulated process maintained by signalling 
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pathways, transcription factors and epigenetic regulation (Botchkarev, 2015). Keratins, K5 and 
K14 which forms keratin intermediate filaments are the two essential proteins involved in the 
proliferation of basal keratinocytes (Candi et al., 2005, Fuchs and Raghavan, 2002, Mack et 
al., 2005). Progression of differentiation in keratinocytes sequentially induce the expression of 
differentiation associated keratins. As the basal keratinocytes move upward the keratin 
intermediate filament structures formed by K5 and K14 are replaced by K1 and K10 filaments. 
K1 and K10 are the markers of early differentiation and start to get expressed in the stratum 
granulosum at the initial stage of cornification (Candi et al., 2005, Fuchs and Raghavan, 2002, 
Mack et al., 2005). At the later stage of cornification filaggrin aggregates keratin filaments into 
compact bundles (Candi et al., 2005, Fuchs and Raghavan, 2002, Mack et al., 2005). Another 
two important structural protein loricrin and involucrin reinforce the cornified layer just under 
the plasma membrane (Candi et al., 2005, Fuchs and Raghavan, 2002, Mack et al., 2005).  
Langerhans cells are skin-specific antigen presenting cells present in the epidermis (Figure 1). 
Dendrites of the Langerhans cells are in contact with the skin surface, continuously sensing for 
foreign antigens (Di Meglio et al., 2011, Nestle et al., 2009a). Melanocytes are another cell 
type of epidermis which produce melanin and protects keratinocytes against UV-radiation-
induced DNA-damage (Figure 1) (Di Meglio et al., 2011, Nestle et al., 2009a). In addition, 
nerve-ending Merkel cells are also present in the epidermis which facilitate light-touch to 
distinguish between different shapes and texture (Di Meglio et al., 2011, Nestle et al., 2009a). 
 
1.1.2 Dermis 
Underneath the basement membrane, networks of loose and dense collagen and elastin fibers 
constitute upper papillary (stratum papillare) and lower reticular (stratum reticulare) layer of 
dermis. The primary role of dermis is to provide stability and flexibility to the skin and nutrients 
to epidermis. Fibroblasts and fibrocytes are the two resident cells maintaining the extracellular 
matrix which provide structural support for blood vessels, sweat glands, sebaceous glands and 
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hair follicles (Figure 1) (Di Meglio et al., 2011, Nestle et al., 2009a, Pasparakis et al., 2014). 
The dermis also hosts immune cells such as dermal dendritic cells, T cells, natural killer cells, 
B cells, mast cells and macrophages (Figure 1) (Di Meglio et al., 2011, Nestle et al., 2009a, 
Pasparakis et al., 2014).  
 
1.1.3 Hypodermis 
The hypodermis is the lowermost layer of skin composed of loose connective tissue and fat 
lobules rich in fibroblast, adipose cells, macrophages and monocytes. The prime function of 
hypodermis is the fat storage and maintenance of body temperature by heat insulation. Adipose 
tissue may contribute to immune response either by direct effect on resident immune cells or 
by modulating immune function in endocrine or paracrine fashion (Desruisseaux et al., 2007, 
Pasparakis et al., 2014).  
 
1.1.4 Immune sentinels in the skin  
In addition to its non-immune functions, the skin serves as immune organ to defend internal 
tissues from foreign agents, while also maintaining homeostasis and preventing excessive 
inflammation. In 1983, skin was coined as skin-associated lymphoid tissue (SALT) due to the 
immune cell trafficking from draining lymph nodes to skin (Streilein, 1983). Since then vast 
amount of research has been performed to decipher the role of different skin resident cells in 
mediating immune response. The skin sentinels mediates both innate and adaptive immune 
responses.  
Keratinocytes are the first line of immune surveillance (Figure 2) and recognizes pathogens 
through pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs) which are 
continuously scanning for pathogen-associated molecular patterns (PAMPs) (Di Meglio et al., 
2011). Keratinocytes express several TLRs either on cell surface such as TLR1 (ligand- 
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lipopeptides), TLR2 (ligands- lipoprotein, peptidoglycans and zymosan), TLR4 (ligand- 
lipopolysaccharide), TLR5 (ligand- Flagellin) and TLR6 (ligand- lipopeptides and lipteichoic 
acid) or on endosomes such as TLR9 (ligand- (unmethylated) CpG-containing DNA) and 
TLR3 (ligand- double stranded RNA) (Lebre et al., 2007, Pivarcsi et al., 2003). In addition, 
keratinocytes express nucleotide-binding domain, leucine-rich repeat (NLR) genes which also 
recognize PAMPs and danger-associated molecular patterns (DAMPs) (Martinon et al., 2009). 
Ligand binding to these receptors leads to inflammasome-mediated activation of pro-
inflammatory signalling cascade (Martinon et al., 2009).  
The nuclear factor-кB (NF-кB) signalling pathway is one of the pivotal pro-inflammatory 
signalling pathway activated in keratinocytes upon pathogen recognition and associated with 
chemokine and cytokine production in response to TNF-α, IL-1 and TLRs (Goldminz et al., 
2013, Pivarcsi et al., 2003). In the normal resting cells, NF-кB (p65) is bound to its inhibitory 
proteins known as inhibitor of kappa B (IкBs) and confined to cytoplasm (Fuchs and Raghavan, 
2002, Goldminz et al., 2013, Mack et al., 2005). In the active state of signalling p65 translocate 
to the nucleus to exert its function. NF-кB pathway targets a variety of genes influencing 
biological processes such as innate and adaptive immunity, inflammation and response against 
stress (Fuchs and Raghavan, 2002, Goldminz et al., 2013, Mack et al., 2005).  
Upon pathogen engagement keratinocytes secrete anti-microbial peptides such as defensins, 
LL-37 and S100s (Di Meglio et al., 2011, Gilliet and Lande, 2008, Lai and Gallo, 2009, Lowes 
et al., 2014). Keratinocytes produce pro-inflammatory cytokines such as IL-1β and IL-18, IL-
6 and TNF in response to external injuries such as infections and trauma (Albanesi et al., 2005, 
Nestle et al., 2009a). To amplify skin inflammation, keratinocytes also secrete chemokines to 
enhance immune cell traffic to the skin by chemotaxis (Albanesi et al., 2005, Di Meglio et al., 
2011, Kim and Krueger, 2015, Lowes et al., 2014). Chemokines bind to G-protein coupled 
receptors (Nedoszytko et al., 2014, Turner et al., 2014). The expression of chemokines, their 
receptor and the adhesion molecule contribute to the homing and migration of leukocytes 
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(Nedoszytko et al., 2014, Turner et al., 2014). For example CXCL1, CXCL2 (ligands of 
CXCR2), CXCL8/IL-8 (ligand of CXCR1, CXCR2) are chemotactic for neutrophils 
granulocytes, which express their receptors and can stimulate their migration to the skin 
(Albanesi et al., 2005, Nedoszytko et al., 2014, Turner et al., 2014). Similarly, CXCL9, 10 and 
11 (receptor-CXCR3) are chemotactic for TH1 cells (Nedoszytko et al., 2014, Turner et al., 
2014). CCL20 (the ligand of CCR6) is another key pro-inflammatory chemokine secreted by 
keratinocytes which chemotactically attracts TH17, TH22 and dendritic cells to the skin 
(Nedoszytko et al., 2014, Turner et al., 2014).  
 
Dendritic cells (DCs) are important in the immuno-surveillance of the skin (Figure 2) and are 
specialized in antigen presentation. DCs in skin migrates to lymph nodes where they present 
the antigen and drive the activation and differentiation of T cells. DCs serve as an essential link 
between innate and adaptive immunity. In addition, DCs secrete pro-inflammatory mediators 
(inflammatory DCs) (Bieber, 2007, Lowes et al., 2005), produce IFNs (plasmacytoid DCs) 
(Gilliet et al., 2008, Nestle et al., 2009a). Antigen presenting Langerhans cells are another 
subset of DCs which reside in epidermis and among the first line of immune sentinels sensing 
the foreign particles (Nestle et al., 2009a, Pasparakis et al., 2014). Moreover, migratory dermal 
DCs are potent regulator of T-cell proliferation in draining lymph nodes (Nestle et al., 2009a, 
Pasparakis et al., 2014). 
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Figure 2: Skin immune sentinels. Reproduced with permission from Nestle et al., 2014. 
Copyright Springer Nature. 
 
Both cytotoxic (CD8+) and helper (CD4+) T-cells are present in the skin and mediate acquired 
immune response (Figure 2) (Di Meglio et al., 2011, Nestle et al., 2009a, Pasparakis et al., 
2014). Normal skin harbours twice the amount of T-cell present in circulation (Clark et al., 
2006). TH1, TH2, TH17, TH22 and regulatory T cells are the main subsets of CD4+ T-cell 
mediating the immune response to different pathological insults. TH1 cells mediates anti-viral 
and anti-tumour response of the skin, while TH17 cells mediate anti-bacterial and anti-fungal 
responses. In addition, TH2 cells facilitates immune response to different allergens and parasites 
(Di Meglio et al., 2011, Nestle et al., 2009a, Pasparakis et al., 2014).   
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Neutrophils are a part of innate immunity and another source of antimicrobial peptides and 
are rapidly recruited to skin upon bacterial infections in response to chemokines secreted by 
keratinocytes (Figure 2) (Abtin et al., 2014, Albanesi et al., 2005). 
Mast cells, macrophages, NKT cells and innate lymphoid cells are the other immune 
sentinels either present in skin or in contact via trafficking through circulation to mediate 
immune response towards internal or external immune triggers (Figure 2) (Di Meglio et al., 
2011, Jenkins et al., 2011, Nestle et al., 2009a, Pasparakis et al., 2014, St John et al., 2011, 
Villanova et al., 2014).  
Communication among the skin resident cells as well as the trafficking immune cells is critical 
to maintain skin homeostasis and to provide an appropriate response to the invading foreign 
triggers. However, failure in the crosstalk among skin resident and trafficking immune cells 
and their responses could result in chronic auto-inflammatory diseases, such as psoriasis. 
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1.2 Psoriasis  
Psoriasis is the most common immune-mediated inflammatory skin disease in adults, affecting 
2-3% of world population with higher prevalence in north American, Canadian and European 
population than African and Asian populations (Naldi, 2004). It is a lifelong chronic disease 
with spontaneous remission and exacerbations (Lowes et al., 2014, Nestle et al., 2009b, Perera 
et al., 2012). While the majority of patients have mild disease, approximately one third of the 
psoriasis patients have moderate to severe psoriasis with more than 10% of the body covered 
with psoriatic lesions (Lowes et al., 2014). Psoriasis impairs the quality of life substantially, 
which is comparable to systemic lifelong disease such as diabetes (Rapp et al., 1999). While 
psoriasis was previously considered as merely a skin disease, today it is considered a systemic 
disease with several comorbidities such as psoriatic arthritis, inflammatory bowel disease, 
depression and metabolic syndrome such as obesity, hypertension, and insulin resistance 
(Javitz et al., 2002, Lowes et al., 2014, Sohn et al., 2006, Yu et al., 2009).  
Plaque psoriasis or psoriasis vulgaris is the most prevalent type of the disease, typically 
manifested as red plaques with demarcated silvery-white dry scales located on elbows, knees, 
scalp and face (Lowes et al., 2014, Nestle et al., 2009b, Perera et al., 2012). Apart from the 
plaque psoriasis there are other less common types of psoriasis such as guttate, inverse and 
pustular psoriasis.  
Histologically, psoriasis lesions are marked by thickened epidermis with significant structural 
alterations such as parakeratosis (retention of nuclei within the cells of the stratum corneum), 
acanthosis (thickening of epidermis), papillomatosis (rete ridge formation), hypogranulosis 
(loss of granular layer) and massive infiltration of immune cells (DCs, TH1, TH17, and TH22 
cells) within the papillary dermis and epidermis and neutrophil microabscesses (Figure 3) (Kim 
and Krueger, 2015, Lowes et al., 2007, Lowes et al., 2014, Nestle et al., 2009b, Perera et al., 
2012).  
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Figure 3: Histology of healthy (left) and psoriasis (right) skin. Courtesy of Dr. Britta Krynitz 
(Department of pathology, Karolinska Institutet).    
 
1.2.1 Genetics of psoriasis  
Population and family-based studies in the 1960s revealed a higher incidence of psoriasis 
among relatives of the psoriasis patients (60-90% heritability) than the general population, 
indicating a genetic predisposition to the disease (Farber and Nall, 1974, Girolomoni et al., 
2015, Nestle et al., 2009b, Perera et al., 2012). Later in 1970s twin studies from Denmark, USA 
and Austria presented a concrete evidence of genetic predisposition in psoriasis, as 
monozygotic twin concordance rate was higher (35-73%) than the dizygotic twins (12-20%) 
(Brandrup et al., 1978, Duffy et al., 1993, Farber et al., 1974). Nevertheless, less than 100% 
concordance rate in monozygotic twins suggested a multifactorial aetiology of the disease, with 
the involvement of environmental factors in addition to the genetic contribution (Elder et al., 
1994, Farber and Nall, 1974, Girolomoni et al., 2015, Nestle et al., 2009b, Perera et al., 2012, 
Watson et al., 1972). Since then at least 36 genomic susceptibility loci have been identified and 
associated with psoriasis (Ray-Jones et al., 2016, Tsoi et al., 2012, Tsoi et al., 2017). The 
psoriasis susceptibility-1 (PSORS1) region was first identified as a potential susceptibility 
locus in 1970s. PSORS1 corresponds to major histocompatibility complex (MHC) and  the key 
associated allele in class I MHC molecule HLA-C is HLA-Cw*0602 which is present in 40-
60% of psoriasis patients and confers a 20-fold higher risk of psoriasis, however, approximately 
only 1 out of 10 HLA-Cw*0602 carriers develop psoriasis. (Elder, 2017, Perera et al., 2012, 
Russell et al., 1972, Tiilikainen et al., 1980). Over the years, genome wide association studies 
(GWAS) led to advancement in psoriasis genetics and identified genes involve in the psoriasis 
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pathogenesis and progression and most of them belong to adaptive immunity (such as IL-
23/Th-17 axis) innate immunity (NF-кB pathway genes), and keratinocytes (such as genes 
regulating epidermal differentiation) (Kim and Krueger, 2015, Lowes et al., 2014, Ray-Jones 
et al., 2016).  
Despite the discovery of a large number of susceptibility genes in psoriasis, there is still a 
missing heritability which cannot be explained by the combination of all the known factors 
(Pivarcsi et al., 2014). Genome wide association studies focuses on the protein coding genes 
and the noncoding regulators such as miRNAs have not been studied in vast details (Pivarcsi 
et al., 2014).   
 
1.2.2 Immunopathogenesis of psoriasis 
Environmental factors such as injury, trauma, stress, alcohol, smoking and infections may 
trigger psoriasis in genetically predisposed individuals (Perera et al., 2012). Recently studies 
have suggested a role of autoantigens in psoriasis such as i) cathelicidin (LL37), a keratinocyte 
and neutrophils-derived antimicrobial peptide which meditates DC activation leading to T cell 
expansion and activation (Lande et al., 2014), ii) cytosolic phospholipase A2 lipid antigen, 
(PLA2G4D), a keratinocyte and mast cell-derived lipid antigen recognized by CD1a- restricted 
T cells, thus inducing IL-17A and IL-22 production (Cheung et al., 2016), iii) HLA-C*06:02-
restricted melanocyte-derived antigen, a disintegrin and metalloprotease domain containing 
thrombospondin type 1 motif- like 5 (ADAMTSL5) which activates TH17 cells (Arakawa et 
al., 2015). The role of autoantigen is still a budding concept in psoriasis and more clinical 
evidences are required to establish the pathogenic role of one or more autoantigens.    
The current model of psoriasis initiation banks on a key finding which demonstrated that 
psoriatic skin extract was able to activate plasmacytoid dendritic cells (pDCs) mediated 
production of IFNs via cathelicidine antimicrobial peptide LL37/DNA complex (Lande et al., 
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2014, Nestle et al., 2009a). According to this model stressed keratinocytes release self-DNA 
and RNA, which binds to LL37, and activates pDCs in TLR9- or TLR7-dependent manner to 
produce interferon-α (IFN-α) (Lowes et al., 2014, Nestle et al., 2009b, Perera et al., 2012). 
More recently, it has been shown that LL37/RNA complex can also induce myeloid dendritic 
cells through TLR8 (Lowes et al., 2014). Interleukin-1β (IL-1β), IL-6 and tumour necrosis 
factor (TNF-α) which are produced by keratinocytes along with pDCs derived IFN-α activates 
dermal DCs (Lowes et al., 2014, Nestle et al., 2009b, Perera et al., 2012). Activated dermal 
dendritic cells (DCs) migrate to the skin draining lymph nodes and present an unknown antigen 
to encourage naive T-cells to differentiate in to TH1 and TH17 cells (Lowes et al., 2014, Nestle 
et al., 2009b, Perera et al., 2012). DC-derived IL-12 and IL-23 are the drivers of this 
differentiation and are required for expansion and survival of TH1 and TH17 cells respectively 
(Figure 4) (Lowes et al., 2014, Nestle et al., 2009b, Perera et al., 2012).  
 
1.2.2.1 THelper cells: help gone wrong   
T cells are present in high number in psoriasis (Zaba et al., 2010) and the pivotal role of T cells 
was first evidenced by the potential of chimeric anti-CD4 antibody to treat psoriasis (Prinz et 
al., 1991). These findings were further corroborated by the mouse model of psoriasis (non-
lesional skin transplantation on to severe combined immune-deficient mice), where psoriasis 
developed after injection of autologous activated CD4+ T cells (Boyman et al., 2004).  For 
many years psoriasis has been thought to be a TH1-mediated disease and even after emergence 
of a central role of TH17 cells in mediating psoriasis pathogenesis, TH1 cells still remain an 
accessory to the disease (Lowes et al., 2014, Nestle et al., 2009b, Perera et al., 2012). TH1 cells 
are present in high numbers in psoriasis and TH1-mediated anti-viral responses are enriched in 
psoriasis skin (Kagami et al., 2010, Lowes et al., 2014, Nestle et al., 2009b, Perera et al., 2012, 
Szabo et al., 1998, Uyemura et al., 1993). TH1 cells express CXC-chemokine receptor 3 
(CXCR3) and CC-chemokine receptor 4 (CCR4) which respond to chemo-attractants such as 
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CXCL9, 10, 11 released by keratinocytes and myeloid cells and migrate to psoriatic lesions. 
IFN-γ and TNF-α are the two main cytokines mediating TH1 responses in psoriasis (Figure 4) 
(Lowes et al., 2007, Lowes et al., 2014, Nestle et al., 2009b, Perera et al., 2012).  
Recent development in the psoriasis research have revealed a central role for TH17 cells (Lowes 
et al., 2008, Wilson et al., 2007), in the disease pathogenesis and progression. There is a higher 
magnitude of infiltrating TH17 cells in psoriasis lesions (Chan et al., 2006, Kagami et al., 2010, 
Lowes et al., 2014, Nestle et al., 2009b, Perera et al., 2012, Wilson et al., 2007). TH17 cells 
differ from classical TH1 and TH2 by their ability to produce IL-17A along with IL-17F and IL-
22 (Martin et al., 2013). The genome wide association studies identified that several genes 
associated with psoriasis belong to the IL-23 and IL-17 signalling pathway (Lowes et al., 2014, 
Martin et al., 2013, Nair et al., 2009, Nestle et al., 2009a, Nestle et al., 2009b, Perera et al., 
2012, Veal et al., 2001). Infiltrating TH17 cells express CCR4 and CCR6 and attracted to the 
site of lesion by CCL20 secreted by keratinocytes and DCs (Figure 4) (Albanesi et al., 2001, 
Harper et al., 2009, Martin et al., 2013). A recent study have shown that a subset of TH17 cells 
can also produce IFN-γ together with IL-17A (Cheuk et al., 2017, Zielinski et al., 2012).  
Infiltrating TH22 cells producing IL-22 are also enriched in psoriasis (Kagami et al., 2010, 
Nestle et al., 2009b, Perera et al., 2012, Wolk et al., 2006). TH22 cell express skin homing 
markers CCR4, CCR6 and CCR10 and respond to CCL20 secreted by keratinocytes (Figure 
4) (Perera et al., 2012, Wolk et al., 2006).  
 
1.2.2.2 Keratinocytes: amplifiers of inflammation  
Keratinocytes are key structural cells in maintaining psoriasis hallmarks. In psoriasis, 
keratinocytes hyper-proliferate, undergo an aberrant differentiation program and produce pro-
inflammatory cytokines and chemokines (Figure 4). Keratinocyte-specific genes such as late 
cornified envelope (LCE) are present in psoriasis genetic susceptibility locus (Capon et al., 
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1999a, Capon et al., 1999b, de Cid et al., 2009, Perera et al., 2012, Zhang et al., 2009) and there 
is an enrichment of keratinocytes anti-microbial (IL-17/IL-22) and anti-viral (IFN-γ) response 
gene sets in psoriasis transcriptome (Lowes et al., 2014, Perera et al., 2012)  
The role of keratinocytes in psoriasis is further supported by mouse models in which 
keratinocyte-specific genetic alterations have resulted in psoriasis-like symptoms. For 
example, mice with targeted deletion of JUN, JUNB or SOCS3 in keratinocytes spontaneously 
developed inflammation in the skin (Uto-Konomi et al., 2012, Zenz et al., 2005) and mice with 
constitutive activation of signal transducer and activator of transcription 3 (STAT3) or 
overexpression of IL-17C in keratinocytes developed psoriasis like inflammation (Johnston et 
al., 2013, Sano et al., 2005).  
Furthermore, keratinocytes express receptors for IL-17A (IL-17R), IFN-γ (IFN-γR) and IL-22 
(IL10R/IL22R) in psoriasis (Lowes et al., 2014, Martin et al., 2013, Nestle et al., 2009b, Perera 
et al., 2012). Keratinocytes are the major source of IL-1β, a cytokine required for naïve T cell 
differentiation to TH17/TH1 cells and their activation (Debets et al., 1997, Kim and Krueger, 
2015, Lowes et al., 2014, Murphy et al., 2000, Nestle et al., 2009b, Perera et al., 2012). The 
cross-talk of keratinocytes with TH17 cells via IL-17A and CCL20 and with TH1 cells via IFN-
γ and CXCL9, 10, 11 is important in disease progression. Upon stimulation with IL-17A 
keratinocytes produce CCL20 and IL-8/CXCL8 (Albanesi et al., 2005, Harper et al., 2009, Kim 
and Krueger, 2015, Lowes et al., 2014, Nestle et al., 2009b, Perera et al., 2012). CCL20 is a 
chemokine which recruits TH17 and myeloid DCs to the site of psoriatic lesions (Kim and 
Krueger, 2015, Lowes et al., 2014, Nestle et al., 2009b, Perera et al., 2012) while IL-8 is a 
chemoattractant for neutrophils and recruits them to the site of lesions (Albanesi et al., 2005, 
Albanesi et al., 2001, Kim and Krueger, 2015, Lowes et al., 2014, Nestle et al., 2009b, Perera 
et al., 2012). Furthermore, IL-17A induces keratinocytes to produce antimicrobial peptides 
(AMPs)-defensins and S100As proteins (S100A7, A8, and A9) to induce and enhance 
inflammatory responses (Kim and Krueger, 2015, Lowes et al., 2014, Nestle et al., 2009b, 
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Nograles et al., 2008, Perera et al., 2012). IFN-γ stimulates keratinocytes to produce 
inflammatory cytokines- IL-6, anti-viral proteins and chemokines CXCL9, 10 and 11 which 
recruits TH1 cells (Albanesi et al., 2005, Albanesi et al., 2001, Kim and Krueger, 2015, Lowes 
et al., 2014, Nestle et al., 2009b, Perera et al., 2012). In addition, IL-22 synergises with IL-17A 
and enhances production of matrix metalloproteinases (MMPs) and AMPs from keratinocytes 
to induce rete ridge formation in psoriasis (Wolk et al., 2006). In summary, keratinocytes are 
the key element in the auto-inflammatory loop of psoriasis and act as an amplifier of cellular 
inflammatory signals.  
 
1.2.2.3 Cytokine networks in psoriasis  
Cytokines are class of small proteins involved in cell signalling and mediates autocrine, 
paracrine and endocrine signalling as immunomodulating agents. Psoriasis-associated cytokine 
networks are discussed in the following section.  
IFN-γ belongs to type II family of IFNs and mainly produced by TH1, TH17, TC, NK and NKT 
cells (Figure 4) (Cheuk et al., 2017, Hassan-Zahraee et al., 1998, Perera et al., 2012, Zielinski 
et al., 2012). IFN-γ is important for myeloid dendritic cells to produces IL-12 and IL-23, thus 
regulating the TH1 and TH17 cell differentiation. Keratinocytes harbour IFN-γ receptor, which 
upon binding to IFN-γ initiates inflammatory and anti-viral responses of keratinocytes via the 
JAK1-2/STAT1 signalling cascade (Ramana et al., 2002). IFN-γ-induced chemokines and 
cytokines such as CXCL 9, 10, 11 and IL-6 has been shown to be important in psoriasis by 
regulating T-cell trafficking and inflammation (Kanda et al., 2007). Recently a study 
demonstrated that a single intradermal injection of IFN-γ resulted in inflammation in both non-
lesional psoriatic and healthy skin (Johnson-Huang et al., 2012). Elevated expression of IFN-γ 
mRNA has been shown in psoriasis skin lesions along with increased levels of IFN-γ in serum 
of psoriasis patients (Abdallah et al., 2009, Lowes et al., 2014). The important role of IFN-γ in 
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psoriasis is further corroborated by transcriptomic analysis of psoriasis lesional skin, which 
revealed enrichment of IFN-γ/STAT1 related genes among the differentially expressed genes 
(Swindell et al., 2013). Furthermore, STAT1 expression is increased in psoriasis skin along 
with increased phosphorylation of p-STAT1 (Hald et al., 2013). Therapeutically, anti-IFN-γ 
(HuZAF) has been shown to have some efficacy in treating psoriasis patients (Harden et al., 
2015). 
TNF-α regulates cellular processes such as inflammation, differentiation, proliferation, cell 
growth, survival and apoptosis (Gaur and Aggarwal, 2003, Locksley et al., 2001). It is mainly 
produced by mast cells, DCs, TH1 and TH17 cells (Nestle et al., 2009b, Perera et al., 2012). 
TNF-α play an important role in the activation of DCs in psoriasis and anti-TNFs (such as 
etanercept, adalimumab and infliximab ) have shown great efficacy to treat psoriasis and are 
the first line of drugs to treat psoriasis in some countries (Yost and Gudjonsson, 2009).  
Downstream effects of TNF-α are mainly mediated by i) NF-кB activation leading to increase 
in inflammatory response via IL8 and CCL20; ii) mitogen-activated protein kinase (MAPK) 
and c-JUN promoting cellular proliferation and differentiation; and iii) death signalling 
regulating cell growth survival and apoptosis (Gaur and Aggarwal, 2003, Locksley et al., 
2001).   
IL-23 has critical role in psoriasis initiation by regulating TH17 differentiation and maturation 
(Figure 4) (McGeachy et al., 2009, Tonel et al., 2010). Myeloid DCs and probably 
keratinocytes are rich source of IL-23 in psoriasis (Di Meglio and Nestle, 2010, Li et al., 2018, 
Piskin et al., 2006, Ramnath et al., 2015, Tonel et al., 2010). The essential role of IL-23 in 
psoriasis is further supported by mouse models where intradermal injection of IL-23 or 
overexpression of IL-12/23p40 in murine keratinocytes resulted in the development of 
psoriasis-like skin inflammation (Chan et al., 2006, Di Meglio and Nestle, 2010, Lowes et al., 
2014). In addition, biological treatment targeting the common p40 subunit of IL-23 and IL-12 
(ustekinumab) or IL-23-specific p19 subunit (tildrakizumab, guselkumab and risankizumab) 
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have shown great treatment responses in treating psoriasis (Girolomoni et al., 2017, Savage et 
al., 2015).    
IL-17A is central in psoriasis pathogenesis as biologics specifically targeting IL-17A 
(secukinumab: neutralizing IL-17A) have shown remarkable efficacies and have been 
approved to treat psoriasis (Hueber et al., 2010, Martin et al., 2013). The essential role of IL-
17 in psoriasis pathogenesis is further evidenced by higher gene expression and protein levels 
of IL-17A, F and C in psoriatic lesions compared with non-lesional skin (Martin et al., 2013). 
IL-17A act on a variety of cells including keratinocytes, endothelial cells, fibroblasts, and 
monocytes (Harper et al., 2009, Martin et al., 2013, Yao et al., 1997). Together with IL-17F, 
IL-17A induces keratinocytes to produce psoriasis associated factors like cytokines, β-
defensins, antimicrobial peptides (S100s protein family) and chemo-attractants such as IL-8, 
CCL20, and CCL2 to attract neutrophils, TH17 cells, macrophages and monocytes (Figure 4) 
(Guttman-Yassky et al., 2008, Harper et al., 2009, Martin et al., 2013, Nograles et al., 2008). 
Furthermore, IL-17A synergises with TNF-α responses and activates NF-кB signalling 
pathway (Martin et al., 2013). Act-1 is directly downstream of IL17R which binds to the 
intracellular arm of the IL17R and can activate two different signalling pathways (Martin et al., 
2013). Act-1 and TRAF interaction activates NF-кB pathway to induce inflammatory 
mediators such as IL-8, TNF and CCL20 (Schwandner et al., 2000). Act-1 can also directly 
bind to TRAF5 in a TRAF6-indendpendent manner thus, stabilizing the inflammatory mRNAs 
(Hartupee et al., 2007).    
IL-17C is another member of IL-17 cytokine family produced by keratinocytes in psoriasis 
and has been shown to act on keratinocytes to stimulate β-defensin 2 and granulocyte colony 
stimulating factor (Martin et al., 2013, Ramirez-Carrozzi et al., 2011). Furthermore, 
keratinocyte-specific overexpression of IL-17C promoted psoriasis-like skin inflammation in 
mice model (Johnston et al., 2013).  
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Figure 4: Model of psoriasis pathogenesis. Reproduced with permission from Perera et al., 
2012. Copyright Annual Reviews.  
 
IL-22 is produced by TH17, TH22, NKT and γδT cells (Zenewicz and Flavell, 2011).  IL-22 
belongs to the IL10 family of cytokines and binds to chains of IL10R and IL22RA1, expressed 
majorly on non-immune cells such as keratinocytes (Sabat et al., 2014, Zenewicz and Flavell, 
2011). IL-22 is a pro-inflammatory cytokine which acts via JAK1/3/STAT3 axis and regulates 
expression of AMPs and MMPs (Sestito et al., 2011, Wolk et al., 2006). Histologically, IL-22 
induces acanthosis in psoriasis by promoting proliferation and blocking differentiation of 
keratinocytes (Figure 4) (Boniface et al., 2005). Therapeutically, targeting JAK/STAT axis in 
psoriasis have been shown to be efficacious (Welsch et al., 2017).  
  19 
 
1.2.3 Disease models of psoriasis  
With the exception of a few cases in primates, psoriasis is a human specific disease 
(Gudjonsson et al., 2007, Lowes et al., 2014, Nestle et al., 2009b). Over the years several 
murine models have been implicated in psoriasis research with some features resembling to the 
human disease (Gudjonsson et al., 2007, Lowes et al., 2014, Nestle et al., 2009b). They can be 
divided in three major types: genetic model, inducible model and xenograft model (Gudjonsson 
et al., 2007, Lowes et al., 2014, Nestle et al., 2009b). In genetic models of psoriasis, researchers 
have targeted a specific gene(s) to observe their functional role in psoriasis pathogenesis. For 
example, JUN/JUNB deletion in keratinocytes led to psoriasis-like skin lesions as well as joint 
symptoms (psoriatic arthritis), IкB-kinase-β deletion in keratinocytes, STAT3 and TGF-β 
constitutive activation in keratinocytes led to spontaneous development of psoriasis-like skin 
inflammation (Gudjonsson et al., 2007, Lowes et al., 2014, Nestle et al., 2009b, Pasparakis et 
al., 2002, Sano et al., 2005, Zenz et al., 2005). Recently a study has shown that the keratinocyte 
specific overexpression of IL-17C in mouse promoted psoriasis like inflammation (Johnston et 
al., 2013).  
A widely used inducible psoriasis model is the imiquimod-induced (TLR7/8 agonist) mouse 
model of psoriasis where imiquimod is applied on the ear and shaved back skin of wild type 
mice to generate psoriasis-like inflammation (Gudjonsson et al., 2007, Lowes et al., 2014, 
Nestle et al., 2009b, van der Fits et al., 2009). This is an acute model which recapitulates almost 
all the psoriasis features most importantly erythema, scaling and skin thickness together with 
activation of IL-23/IL-17 axis (Gudjonsson et al., 2007, Lowes et al., 2014, Nestle et al., 2009b, 
van der Fits et al., 2009). In addition, IL-23 intradermal injection in mice has also been shown 
to induce psoriasis-like skin inflammation (Chan et al., 2006).  
In the xenograft model of psoriasis, non-lesional human skin is grafted on the back of AGR 
mice (lacking B and T cells and IFN-γ receptor) (Boyman et al., 2004, Gudjonsson et al., 2007, 
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Lowes et al., 2014, Nestle et al., 2009b, Nestle and Nickoloff, 2005). The non-lesional skin is 
converted to lesional skin over the weeks presenting the unique features of psoriasis like 
acanthosis, loss of granular layer, dermal and epidermal T cell infiltration (Boyman et al., 2004, 
Gudjonsson et al., 2007, Lowes et al., 2014, Nestle et al., 2009b). However, the difficulty of 
getting large human skin for the grafting is a limiting factor of this model (Gudjonsson et al., 
2007, Lowes et al., 2014, Nestle et al., 2009b).   
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1.3 MicroRNAs 
MicroRNAs (miRNA) are among the shortest (~ 22 nucleotides in length) functional class of 
RNA in eukaryotes and are vital in post-transcriptional regulation of gene expression (Ameres 
and Zamore, 2013, Bartel, 2004, 2009). In 1993, the first ever miRNA- lin-4 was discovered 
in C. elegans where a gene (lin-4) was found to encode for a small RNA rather than protein 
(Lee et al., 1993). Lin-4 RNA was found to regulate LIN-14 proteins through antisense 
complementarity at 3’ untranslated region (3’ UTR) of LIN-14 (Lee et al., 1993). For many 
years these tiny regulators were under appreciated as their existence were limited to nematodes. 
However, discovery of let-7 RNA in C. elegans (Reinhart et al., 2000, Slack et al., 2000) and 
homologs of let-7 in human and fly genomes (Pasquinelli et al., 2000) pointed towards an 
exciting class of non-coding RNAs. 
To date 2588 mature human miRNAs are registered in miRbase21 (http://www.mirbase.org/). 
MiRNAs plays crucial role in regulating gene expression as evidenced by the maintained 
sequence complementarity among miRNAs and more than 60% of human mRNAs during the 
course of selection pressure through evolution (Ameres and Zamore, 2013, Friedman et al., 
2009, Ha and Kim, 2014, Jonas and Izaurralde, 2015). In addition, Dicer1 knockout in mice 
led to lethality as Dicer1-null embryos died around 7.5 days of gestation (Bernstein et al., 
2003). Similarly, antisense-mediated depletion of 46 miRNAs in early drosophila embryo led 
to impaired development (Leaman et al., 2005).  
In humans, the majority of miRNAs are encoded in introns of non-coding or coding transcripts. 
Often miRNAs loci are present in close proximity and organised as a poly-cistronic 
transcriptional clusters which usually transcribed together (Ha and Kim, 2014). Often miRNAs 
which are present in the intron of protein-coding genes share the same promoter as the host 
genes (Monteys et al., 2010, Ozsolak et al., 2008). However, some miRNAs have multiple 
transcription start sites and can have their own promoter regions (Monteys et al., 2010, Ozsolak 
et al., 2008). Biogenesis of miRNAs is tightly regulated process which is maintained by 
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transcription factors (p53, MYC, ZEB1/2 and MYOD1), DNA methylation and histone 
modification (Davis-Dusenbery and Hata, 2010, Krol et al., 2010).    
 
1.3.1 The biogenesis of miRNAs 
In eukaryotes, miRNA biogenesis is regulated transcriptionally as well as post-transcriptionally 
and dysfunction in biogenesis is often related to development of disease conditions (Ameres 
and Zamore, 2013, Ha and Kim, 2014, Jonas and Izaurralde, 2015). MiRNAs are transcribed 
as long primary-miRNAs (pri-miRNAs) containing single or multiple miRNAs by RNA 
polymerase II (Figure 5) (Ameres and Zamore, 2013, Ha and Kim, 2014, Jonas and Izaurralde, 
2015, Lee et al., 2004). A stem loop structure of ~ 60 nucleotide pre-miRNA is cleaved from 
the pri-miRNA by an RNase III enzyme Drosha in the nucleus (Figure 5) (Ameres and Zamore, 
2013, Denli et al., 2004, Gregory et al., 2004). Drosha is a part of a bigger nuclear complex 
called the microprocessor, containing Drosha and double stranded (ds) RNA binding protein 
named DGCR8 (Figure 5) (Ameres and Zamore, 2013, Denli et al., 2004, Gregory et al., 2004). 
The excised pre-miRNAs are then transported to cytoplasm by nuclear transport receptor 
exportin 5 which recognises the end and the stem of the precursor-miRNA (Figure 5) (pre-
miRNAs) (Ameres and Zamore, 2013, Okada et al., 2009, Yi et al., 2003). Once in cytoplasm, 
a ds-miRNA-miRNA duplex is diced from the pre-miRNAs by another RNase III enzyme 
called Dicer (Figure 5) (Ameres and Zamore, 2013, Zhang et al., 2002, Zhang et al., 2004). 
Dicer recognises and cuts at the certain distance from stem, liberating the loop from the pre-
miRNAs (Ameres and Zamore, 2013, Zhang et al., 2002, Zhang et al., 2004). Both 5’ and 3’ 
strand of the miRNA-miRNA duplex can form a mature single strand of either 5p or 3p miRNA 
(Ha and Kim, 2014). After the processing of miRNAs either 5’ or 3’ miRNAs can be loaded to 
RISC complex and guide AGO proteins to the target mRNA to repress their expression via 
seed match sequence binding (Figure 5) (Ameres and Zamore, 2013). Binding of miRNAs to 
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mRNAs can lead to either translational repression or mRNA degradation (Ameres and Zamore, 
2013).  
 
Figure 5: Schematic of miRNA biogenesis. Reproduced with permission from Ameres et al., 
2013. Copyright Springer Nature. 
 
1.3.2 Mode of action of miRNAs 
MiRNAs exert their function by either directly degrading the complementary target mRNAs 
(Bagga et al., 2005, Giraldez et al., 2006, Jing et al., 2005, Lim et al., 2005) or blocking their 
translation (Figure 6) (Ameres and Zamore, 2013, Ha and Kim, 2014, Hausser and Zavolan, 
2014, Jonas and Izaurralde, 2015). Each miRNA can regulate hundreds of genes, often these 
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regulated targets are within the same pathway (Bartel, 2009). MiRNAs are an integral part of 
RNA induced silencing complex (RISC), where they associate with Argonaute (AGO) family 
proteins- the catalytic unit of the RISC (Figure 6) (Ameres and Zamore, 2013, Ha and Kim, 
2014, Jonas and Izaurralde, 2015). Regulation of mRNAs via miRNAs is mostly dependent on 
seed sequence of miRNAs. Seed sequence is a 6-8 nucleotide long sequence present on 5’ end 
of the miRNAs (usually between positions 2 to 8) through which miRNAs binds to the seed 
matches, often present at 3’ UTR of mRNAs (Ameres and Zamore, 2013, Forman and Coller, 
2010, Grimson et al., 2007, Ha and Kim, 2014, Jonas and Izaurralde, 2015).  
 
Figure 6: Mode of action of miRNAs. Reproduced and modified with permission from Ameres 
et al., 2013. Copyright Springer Nature. 
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The effects of miRNAs on the regulation of a target mRNAs is relatively mild, however often 
their gene targets regulate the same cellular pathways, thus even a small regulation of target 
mRNAs leads to a vast impact on the biological processes (Ameres and Zamore, 2013). 
MiRNAs with the same seed sequence belong to the same family (with overlapping target 
genes), while miRNAs with same origin and primary transcript belong to the same cluster 
(Ameres and Zamore, 2013, Ha and Kim, 2014, Jonas and Izaurralde, 2015). 
MiRNA-mediated degradation of target mRNAs is directed by enzymes involved in 5’-3’ 
mRNA decay pathway, where final degradation is facilitated by exoribonuclease 1(XRN1)  
(Figure 6) (Ameres and Zamore, 2013, Ha and Kim, 2014, Jonas and Izaurralde, 2015). 
Translational repression is an early event after miRNAs expression and according to evolving 
consensus, it supresses cap dependent translation at initiation (Jonas and Izaurralde, 2015).  
 
1.3.3 MiRNAs in diseases 
Considering the diverse expression pattern and tight regulation of miRNAs targeting a 
significant number of mRNA targets, it is not surprising that miRNAs have been implicated in 
several diseases such as cancer, cardiovascular disease, immunological disease and many other 
diseases (Lovendorf and Skov, 2015, Mehta and Baltimore, 2016, Mendell and Olson, 2012, 
Rupaimoole and Slack, 2017). First implication of miRNAs in diseases regulation originated 
from cancer studies. Cell-specific miRNA expression patterns are useful for tumour prognosis 
and classification (Calin and Croce, 2006). Tumour-suppressive miRNAs such as let-7, miR-
34a and miR-145 and miR-200 family and oncomiRs such as miR-10b, miR-155 and miR-222 
have been implicated in several different cancer types (Rupaimoole and Slack, 2017). 
MiRNAs have also been also utilized as minimally-invasive biomarkers as they are present and 
are rather stable in body fluids such as blood, serum, plasma, saliva and urine (Hydbring and 
Badalian-Very, 2013). The extracellular miRNAs are either encapsulated in microvesicles or 
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bound to AGO2 protein (Turchinovich et al., 2013). The microvesicles incorporated miRNAs 
are thought to be a part of cell to cell communication, while AGO2 bound miRNAs are majorly 
the result of cell death (Turchinovich et al., 2013). In both the cases miRNAs could serve as 
biomarkers by reflecting a certain stage or a cellular signals.      
MiRNAs have a unique expression signature in almost all the human diseases, leading to an 
opportunity to overexpress (with miRNA mimics) or inhibit (with miRNA inhibitors) a 
particular miRNA to counteract its effect in the disease scenario (Lovendorf and Skov, 2015, 
Mendell and Olson, 2012, Rupaimoole and Slack, 2017). Therapeutically, miRNAs has been 
targeted to treat different diseases, for example miR-122 for Hepatitis C infection, miR-34 for 
liver cancer, miR-208 for cardio-metabolic disease and miR-103/105 for insulin resistance 
(Elmen et al., 2008, Li and Rana, 2014, Montgomery et al., 2011, Rupaimoole and Slack, 
2017).                     
 
1.3.4 MiRNAs in skin and psoriasis 
Skin-specific knockout of Dicer, a key component of miRNAs biogenesis in mice resulted in 
a halt in production of miRNAs leading to aberrant morphogenesis of stratified epithelial 
tissues and neonatal conditional knockout mice did not survive past post-natal day 4-6, 
indicating a crucial role of miRNAs in skin (Yi and Fuchs, 2010, Yi et al., 2006). Similarly, 
DGCR8 skin-specific knockout mice developed rough and dehydrated skin and mice died at 
neonatal stages (Yi and Fuchs, 2010, Yi et al., 2009).    
In 2007, our group demonstrated for the first time that miRNAs are differentially expressed in 
psoriatic skin (Sonkoly et al., 2007) as compared to healthy skin, but also as compared to 
another inflammatory skin disease, atopic dermatitis. Since then, several studies investigating 
global miRNA expression by microarray or RNA sequencing have shown altered miRNA 
levels in psoriatic plaques (Joyce et al., 2011, Lovendorf et al., 2015, Zibert et al., 2010). One 
of the miRNAs we identified to be up-regulated in psoriasis, miR-203, showed skin-specific 
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expression profile and it became the most studied miRNA in skin (Lena et al., 2008, Sonkoly 
et al., 2008, Sonkoly et al., 2007, Yi et al., 2008). MiR-203 plays a pivotal role in epidermal 
cell differentiation, stratification and skin cancer (Lohcharoenkal et al., 2016, Lovendorf and 
Skov, 2015, Sonkoly et al., 2012, Sonkoly et al., 2007, Yi et al., 2008). MiR-203 targets gene 
suppressor of cytokine signalling SOCS-3 and involved in keratinocytes differentiation and 
immune response (Sonkoly et al., 2007).  
We and others have shown that deregulated miRNAs modulate cellular functions altered in 
psoriasis, such as epidermal differentiation (miR-21, miR-125b, miR-203, miR-99a) (Lerman 
et al., 2011, Sonkoly et al., 2007, Xu et al., 2011), T cell apoptosis (miR-21) (Meisgen et al., 
2012), and keratinocyte-immune cell cross talk (miR-31) (Xu et al., 2013). Therapeutically 
targeting miR-21 has shown potential to treat psoriasis in psoriasis xenograft model and 
psoriasis-like mouse models (Guinea-Viniegra et al., 2014). MiR-146a is also upregulated in 
psoriasis (Sonkoly et al., 2007) and negatively regulates TLR2-induced inflammatory 
responses in keratinocytes (Meisgen et al., 2014). Altogether these findings indicate an 
important role of miRNAs in psoriasis pathogenesis, progression and maintenance.  
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2 AIMS 
In this thesis, we aimed to decipher the regulatory networks of cytokines and miRNAs in 
psoriasis pathogenesis, progression and maintenance.  
The objectives of this research were 
 to understand role of miR-146a in psoriasis (Paper I),  
 to identify the miRNA landscape of keratinocytes in psoriasis (Paper II), 
 to explore the role of miR-149 in keratinocytes in psoriasis (Paper III), 
 to determine the effect of the JAK inhibitor tofacitinib on keratinocytes (Paper IV).  
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3 MATERIAL AND METHODS  
 
Patients and healthy donors 
Four mm skin punch biopsies were collected from lesional and non-lesional skin of patients 
with chronic plaque psoriasis or healthy donors of Caucasian origin. Psoriasis patients went 
through a drug washout period of 4 weeks for systemic therapy and 2 weeks for UV treatment 
before sample collection. For genetic analysis, DNA was isolated from 1546 psoriasis patients 
and ethnically matched 1526 control subjects (Stockholm Psoriasis Cohort). All the donors 
provided informed consent for the study. The study was approved by the Stockholm Regional 
Ethics Committee and all the procedure involving human samples were performed according 
to the Declaration of Helsinki’s principles.   
 
Genetic analysis 
To detect genetic association of single nucleotide polymorphism in miR-146a precursor and 
psoriasis, the rs2910164 SNP was genotyped in 1546 psoriasis patients and 1526 control 
subjects. The genotype was detected using QuantStudio 7 Flex and allele-specific TagMan 
MGB probes (Thermo Fisher Scientific, Stockholm Sweden).  Allelic association of rs2910164 
was performed in PLINK v1.07 by using logistic regression with sex as the covariate. Hardy-
Weinberg equilibrium was evaluated using χ2 for each SNP to establish the genetic association.  
 
CD45neg cell isolation  
Skin biopsies were incubated with dispase (5 U/ml) (Thermo Fisher Scientific, Stockholm, 
Sweden) for 14-16 hours at 4˚ C and epidermis was separated from dermis using forceps. To 
obtain single cell suspension, epidermal sheets were further sliced and incubated with trypsin-
 32 
EDTA (Thermo Fisher Scientific, Stockholm, Sweden) for 15 mins at 37˚ C. To tag the 
CD45pos cells, epidermal single cells were incubated with CD45pos microbeads (Miltenyi 
Biotec, Stockholm, Sweden) for 15 mins at 4˚ C. CD45neg cells (majorly keratinocytes) were 
negatively sorted using MACS MS magnetic columns (Miltenyi Biotec, Stockholm, Sweden). 
 
Mice 
Female BL6/miR-146and wild-type (WT) C57BL/6J, 6-8 weeks old mice were obtained 
from Jackson laboratory (Bar Harbor, Maine, USA) and Charles River (Wilmington, Mass, 
USA) respectively. To mimic the initiation phase of psoriasis-like skin inflammation in mice, 
5% imquimod (Aldara cream; MEDA, Stockholm, Sweden) (31.25 mg) was applied on ears 
for 3 consecutive days and mice were sacrificed on day 4. To study the resolution phase of 
psoriasis-like skin inflammation in mice, imiquimod (62.5 mg) was applied to shaved dorsal 
mice skin for 6 consecutive days and followed for 10 days or sacrificed at day 7. Control 
animals were treated with vehicle cream. Symptoms of psoriasis-like skin inflammation such 
as erythema, scaling, and skin thickness were scored (0-none; 1-mild; 2-moderate; 3-severe 
and 4- very severe) by three researchers independently. To overexpress miR-146a in skin, 
complex of miR-146a mimics or scramble controls (Thermo Fisher Scientific, Stockholm 
Sweden) with transfecting agent (In Vivo RNA-LANCEr II) (Bioo Scientific, Austin, Texas, 
USA) were injected intra-dermally in shaved mice dorsal skin at day 1, 2 and 4 in WT mice. 
Imiqimod (62.5 mg) was applied on back skin at day 2, 3 and 4 and mice were sacrificed at day 
5. The animal study was approved by Local Ethics Committee of Stockholm, Sweden (Swedish 
Board of Agriculture).  
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Cell culture, treatments, and transfections 
Human primary keratinocytes were obtained from Thermo Fisher Scientific (Stockholm, 
Sweden) and cultured in Epilife medium (Thermo Fisher Scientific, Stockholm Sweden) with 
1% human keratinocyte growth supplement (HKGS) (Thermo Fisher Scientific, Stockholm, 
Sweden) and 1% penicillin/streptomycin (Thermo Fisher Scientific, Stockholm, Sweden) at 
37˚ C with 5% CO2. To avoid any basal induction of cytokine production by hydrocortisone 
(present in HKGS) keratinocytes were incubated with EpiLife medium without any 
supplements during the experiments. Peripheral blood mononuclear cells (PBMCs) were 
isolated from blood samples of healthy donors, by using Ficoll (GE Healthcare, Stockholm, 
Sweden) density separation.  
For cytokine stimulation experiments, keratinocytes were treated with IL-17A (5, 10, 20, 40, 
80, 100 or 200 ng/ml), IFN-γ (20 ng/ml), IL-1β (10 ng/ml), IL-22 (20 ng/ml), TNF-α (50 
ng/ml), IL-36α (10 ng/ml) and IL-17A+IL-22+TNF-α (100 ng/ml, 10 ng/ml and 25 ng/ml) for 
the specified time points. All the cytokines were purchased from R&D Systems (Minneapolis, 
Minnesota, USA). To block JAK/STAT pathway, human primary keratinocytes were pre-
treated either with JAK1/3 inhibitor- tofacitinib (0.6 µM) (Phizer, Stockholm, Sweden or 
Selleckchem, Houston, Texas, USA) or JAK1/2 inhibitor ruxolitinib (0.3 μM) (Selleckchem, 
Houston, Texas, USA) for 1 hour, followed by treatment of IL-22 or IFN-γ for 1 or 24 hours. 
Dimethyl sulphoxide (DMSO) (Merck, Stockholm Sweden), was used as a vehicle control for 
the inhibitors.  
To judge the functional role of miR-146a or miR-149, third passage, 50-70% confluent human 
primary keratinocytes were transfected with miR-146a/miR-149 mimics (1 nM) (Thermo 
Fisher Scientific, Stockholm, Sweden) or miR-146a/miR-149 inhibitors (50 nM) (Qiagen, 
Stockholm, Sweden) or corresponding negative controls using Lipofectamine 2000 (Thermo 
Fisher Scientific, Stockholm, Sweden) for specified time points.   
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Three-dimensional (3D) epidermal equivalents were procured from MatTek (Ashland, MA, 
USA) and maintained at the air-liquid interphase as recommended by the manufactures. IFN-γ 
(20ng/ml) (R&D Systems, Minneapolis, Minnesota, USA) was added to the 3D epidermal 
equivalent for 72 hours. 3D-epidermal equivalents were either FFPE sectioned and stained with 
hematoxilin/eosin (Histolab, Stockholm, Sweden) or snap frozen for RNA isolation.  
 
RNA extraction   
From cell culture experiments, total RNA was extracted using Trizol (Thermo Fisher Scientific, 
Stockholm, Sweden) and chloroform (Merck, Stockholm Sweden) (phenol-chloroform). Total 
RNA was extracted from animal tissues using tissue-lyser (Qiagen, Stockholm, Sweden) and 
miRNeasy mini kit (Qiagen, Stockholm, Sweden). miRNeasy mini kit (Qiagen, Stockholm, 
Sweden) was also used to isolate total RNA from CD45neg cells or PBMCs. RNA concentration 
was measured using Nanodrop 2000 or Nanodrop one (Thermo Fisher Scientific, Stockholm, 
Sweden). For small RNA sequencing or microarray analysis RNA quality was detected using 
Agilent 2100 Bioanalyzer chip (Agilent, Stockholm, Sweden). RNA samples with RNA 
Integrity Number (RIN) more than 9 were used for small RNA sequencing or microarray.  
 
Small RNA sequencing  
Next generation sequencing for small RNAs was performed at BGI (Beijing Genomics 
Institute, Beijing, China) on RNA isolated from keratinocytes of healthy (n = 9), psoriasis 
lesional and non-lesional donors (n = 9).  Adopters and low expressed tags were trimmed from 
the data and clean reads were aligned to miRBase to detect the known miRNAs. Clean reads 
for putative novel miRNAs of 22-25 nucleotides were aligned to human genome and secondary 
structure (precursor) was predicted using MIREAP algorithm. Differential expression of 
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miRNAs were analysed using Edge-R in Bioconductor (False Discovery Rate < 10%, Fold 
Change > 1.4). Only the miRNAs expressed as 1 transcript per million in at least half of the 
samples of at least one of the groups were considered to be robustly expressed and considered 
for the differential expression analysis.  
 
Transcriptomic profiling  
For transcriptomic analysis, RNA samples were hybridized on Affymetrix Gene Titan ST2.1 
(Stockholm, Sweden) array plate and scanned using Affymetrix Gene Titan microarray scanner 
(Stockholm, Sweden). Data was normalized using Affymetrix standard protocol. Adjusted P-
value < 0.05 or P-value < 0.05, (fold change > 1.4 or > 1.2) were calculated using SAM 
(significance analysis for microarray), using MEV (Multiple Experiment Viewer) (TM4) 
(Howe et al., 2011). Heatmaps were plotted using Morpheus (Broad Institute, https://software. 
broadinstitute.org/morpheus) or MEV (TM4).   
 
Gene enrichment and gene network analysis  
Enrichment analysis was performed using Gene Set Enrichment Analysis (GSEA) software 
(Broad Institute) (Mootha et al., 2003, Subramanian et al., 2005). KEGG pathway enrichment 
or gene ontology was performed using EnrichR (Ma’ayan Laboratory) (Chen et al., 2013, 
Kuleshov et al., 2016). Gene networks were generated using gene ontology clustering (KEGG) 
in Cytoscape using the ClueGo plugin (Bindea et al., 2009).  
 
qRT-PCR 
Total RNA was reverse transcribed either using miRNAs specific primers (miR-146a/miR-
149/miR-941/miR-1307-3p/RNU48) and MicroRNA Reverse Transcription Kit (Thermo 
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Fisher Scientific, Stockholm, Sweden) or using oligo dT and random hexamer (RevertAid First 
Strand cDNA Synthesis Kit) for mRNAs (Thermo Fisher Scientific, Stockholm, Sweden). 
Expression of miR-146a, miR-149, miR-941 and miR-1307-3p was analysed with TaqMan 
probes using QuantStudio Flex 7 (Thermo Fisher Scientific, Stockholm, Sweden). Expression 
of miRNAs was normalised to RNU48 and relative expression was calculated using ΔΔCt 
calculation. Expression of JAK 1, JAK2, JAK3, Tyk2 (Thermo Fischer Scientific, Stockholm, 
Sweden), IL-8, CCL20, S100A7, S100A8, S100A9, EGR1, IL-6, CXCL9, CXCL10 and 
CXCL11 (Integrated DNA Technologies, Coralville, Iowa, USA) was determined using 
TaqMan based predesigned qPCR assays and QuantStudio Flex 7. Gene expression was 
normalized based on housekeeping gene 18S (18S fwd: CGGCTACCACAT CCAAGGAA; 
rev: GCTGGAATTACCGCGGCT, probe: TGCTGGCACCAGACTTGCCC TC) using ΔΔCt 
calculation. Expression of mouse Il-1β, IL-8, Cxccl1, Ccl20, Cxcr2, S100a7, S100a8, S100a9 
and Krt16 was detected by QuantStudio Flex 7 using TaqMan based predesigned qPCR assays 
(Integrated DNA Technologies, Coralville, Iowa, USA). Gene expression was normalized to 
mouse GAPDH.  
 
Immunoblotting 
Cell lysate was resolved on 4-20% gradient gels (Bio-Rad, Stockholm, Sweden) and transferred 
on to the nitrocellulose membrane (Bio-Rad, Stockholm, Sweden). The membrane was blocked 
with 5% milk in phosphate buffer saline (with tween 20) for 1 hour. Immunoblotting was 
performed for p-p65 (1:1000), p-65 (1:1000), pSTAT3 (1:1000), STAT3 (1:1000), pSTAT1 
(1:1000), STAT1 (1:1000), JAK1 (1:1000), JAK2 (1:1000) and JAK3 (1:1000) (Cell 
Signalling Technology, Stockholm, Sweden) at 4˚ C for 12-16 hours. Next day, membranes 
were washed and incubated either with horseradish peroxidase-coupled (HRP) isotype-specific 
anti-rabbit (1:2000) or anti-mouse (1:1000) secondary antibodies, obtained from Dako 
(Agilent, Stockholm, Sweden) for 1-2 hours. Chemiluminescence (GE Healthcare, Stockholm, 
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Sweden) detection system was used to detect the blot signals. HRP-coupled β-Actin (1:20000) 
(Merck, Stockholm Sweden) was used as a loading control. 
 
Histology, immunohistochemistry and immunofluorescence  
Formalin-Fixed Paraffin-Embedded (FFPE) skin sections (6-8 µM thick) were used for 
histology and immunohistochemistry (IHC). Mouse skin section were stained with 
hematoxylin and eosin (H&E) (Histolab, Stockholm, Sweden) and photographed. Epidermal 
thickness was measured using ImageJ software on the histology images. IHC was performed 
for anti-mouse Gr-1 (1:200) (rat monoclonal) and Ki67 (1:200) (rabbit monoclonal) (Cell 
Signalling Technology, Stockholm, Sweden) using ABC and AEC peroxidase (HRP) substrate 
kit (Vectastain) (Vector Laboratories, Burlingame, CA, USA). Gr-1/Ki67 positive cells were 
counted per field of view using ImageJ. To detect nuclear translocation of p65, cells were fixed 
and incubated with p65 antibody (1:500) (Cell Signalling Technology, Stockholm, Sweden) 
and detection was performed using Alexa Fluor 564-conjugated secondary antibody (Thermo 
Fisher Scientific, Stockholm, Sweden). DAPI was used for nuclear staining (Thermo Fisher 
Scientific, Stockholm, Sweden).  
 
In situ hybridization  
In situ hybridization for miR-146a or miR-149 was performed on 6-8 µM thick FFPE skin 
sections. Sections were de-paraffinized and treated with proteinase K (20 μg/ml) (Thermo 
Fisher Scientific, Stockholm, Sweden) for 15 mins at 37˚C and incubated with miR-146a or 
scramble control (55˚C) or miR-149 or scramble probe (53˚C) (double DIG) (Qiagen, 
Stockholm, Sweden) for overnight. Sections were washed with SSC buffer (Thermo Fisher 
Scientific, Stockholm, Sweden) and incubated with alkaline phosphatase-conjugated sheep 
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anti-digoxigenin Fab fragments (1:800) (Roche, Merck, Stockholm, Sweden) for 1 h at room 
temperature. Antibody conjugated probe signal was developed with BM purple alkaline 
phophatase substrate (Roche, Merck, Stockholm, Sweden) for overnight at room temperature. 
 
Laser-capture microdissection 
10 µM thick FFPE mouse skin sections were de-paraffinized and stained with H&E (Histolab, 
Stockholm, Sweden). The epidermal areas were marked with digital pen followed by laser-
section microdissection using Leica LMD7000 (Leica Microsystems, Stockholm, 
Sweden).The laser cut epidermis pieces were collected in a tube containing Proteinase K 
digestion buffer (Qiagen, Stockholm, Sweden) and were further processed for RNA isolation.   
 
ELISA 
Supernatant from keratinocytes cell culture upon miRNA transfections (mimic/inhibition) 
followed by cytokine treatments were collected and stored in -80 ˚C. ELISA for IL-8, CCL20 
or IL-6 (Biolegend, San Diego, California, USA) was performed using manufacturer’s 
instruction.  
 
Neutrophil migration assay 
Primary human neutrophils were isolated from whole blood collected from healthy donors. 
Erythrocytes were removed using dextran sedimentation (2:1 mixture of blood: 6% dextran / 
0.9% NaCl) (Merck, Stockholm, Sweden), followed by hypotonic lysis. Purified neutrophils 
were suspended in EpiLife serum-free keratinocyte growth medium, and 6×105 cells were 
added to the inner chamber of a 3 µm PET membrane cell culture insert (BD Falcon, 
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Erembodegem, Belgium). Cell culture supernatant from keratinocytes transfected with pre-
miR-146a, pre-miR-Ctrl, anti-miR-146a or anti-miR-Ctrl followed by IL-17 treatment was 
added to the outer chamber. After incubation for 1 to 1.5 hours at 37° C in 5% CO2, the 
migrated neutrophils in the outer chamber were quantified by flow cytometry and normalized 
to the culture medium volume by addition of CountBright counting beads (Thermo Fisher 
Scientific, Stockholm, Sweden). 
 
Statistical analysis 
Student’s t-test, Mann-Whitney U test, two-way ANOVA were performed using Prism 6.0 
(Graph Pad Software, La Jolla, USA). P-values < 0.05 were considered to be statistically 
significant. *P < 0.05; **P < 0.01; ***P < 0.001 and ****P < 0.0001. 
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4 RESULTS AND DISCUSSION 
 
4.1 THE ROLE OF MIR-146A IN PSORIASIS  
Genetic variation is one of the strongest component in psoriasis pathogenesis and in recent 
years several psoriasis susceptibility genes have been identified using genome wide association 
studies. In 2007, our group performed the first ever miRNA profiling of psoriasis skin and 
found miR-146a to be upregulated in psoriasis (Sonkoly et al., 2007). Since then, we and other 
groups have shown that miR-146a regulates innate immune functions of keratinocytes and NF-
кB mediated inflammatory signalling in atopic dermatitis (Meisgen et al., 2014, Rebane et al., 
2014). Moreover, naturally aged miR-146a knockout mice developed chronic inflammation 
indicating an important role of miR-146a in inflammation (Boldin et al., 2011, Zhao et al., 
2011). In this study we aimed to investigate the association of a single nucleotide 
polymorphism (SNP) in miR-146a with psoriasis and investigate the function of miR-146a in 
the disease.      
 
4.1.1 Results 
 4.1.1.1 A functional polymorphism of miR-146a is associated with psoriasis  
SNP rs2910164 (G to C) is located in the precursor of miR-146a which result in altered levels 
of miR-146a due to G:U pair to C:U mismatch in the stem region of the miR-146a precursor 
(Jazdzewski et al., 2008). Genotype analysis of this SNP in the Stockholm Psoriasis Cohort 
including DNA samples from psoriasis patients (n=1546) and healthy controls (n=1526) 
revealed a small but significant protective association of the CC genotype compared to GG or 
GC genotype (P=0.03 odds ratio=0.68 95% confidence interval 0.47-0.97) (Paper I, Table 1). 
Because of the strong effect of the HLA-C*06 risk gene for psoriasis, which might hide less 
strong, but significant effect of other genes, next we decided to stratify our cohort based on 
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HLA-C*06 status. Strikingly we observed a strong protective association of rs2910164 to 
psoriasis in HLA-C*06-negative patients (P=0.008 odds ratio=0.53 95% confidence interval 
0.33-0.84) (Paper I, Table 1). Moreover, our analysis revealed a strong protective association 
of rs2910164-CC genotype in psoriasis which protects against the early onset of psoriasis 
(Paper I, Table 1). Altogether, these results indicate a protective association of rs2910164-CC 
genotype to psoriasis.   
 
4.1.1.2 miR-146a knockout mice develop earlier onset of imiquimod- induced 
psoriasis-like skin inflammation  
Next, we aimed to investigate the role of miR-146a in psoriasis in vivo. To this end, imiquimod 
(a ligand of TLR 7/8, and a known inducer of psoriasis-like skin inflammation) (van der Fits et 
al., 2009) was applied on the ear of 6-8 week old female BL6/miR-146and wild-type (WT) 
C57BL/6J for three consecutive days (Figure 7A, Paper I, Figure 1A).  
 
Figure 7: (A) Experimental setup. (B) Skin thickness measured over a course of 4 days of  
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imiquimod treatment. (C-D)Histology for mice skin and quantification of epidermal thickness. 
(E-F) Immunohistochemistry for Ki67 and Gr1. (G) GSEA analysis of psoriasis epidermal and 
IL-17A pathway gene enrichment among the deregulated genes in BL6/miR-146mice ear 
upon imiquimod treatment. Reproduced with permission from Srivastava et al., 2016. 
Copyright Elsevier. 
 
BL6/miR-146mice showed an earlier onset of the disease and a more pronounced 
inflammation compared to the WT mice, assessed by ear thickness which is a commonly used 
measure of skin inflammation in this model (Figure 7B, Paper I, Figure 1B). Histological 
analysis of the ear skin revealed an increased epidermal thickness in the BL6/miR-146mice 
compared to the WT mice (Figure 7C-D, Paper I, Figure 1C-D). Immunohistochemistry for 
proliferation marker Ki67 and neutrophil marker Gr1 depicted increased number of Ki67 
positive and Gr1 positive cells in BL6/miR-146mice, suggesting that keratinocytes were 
more proliferative upon imiquimod application in BL6/miR-146mice and there were higher 
infiltration of neutrophils in these mice (Figure 7E-F, Paper I, Figure 1E-F). Furthermore, 
GSEA analysis on whole upregulated transcriptome of BL6/miR-146mice demonstrated a 
significant enrichment of genes upregulated in psoriasis epidermis along with IL-17 pathway 
genes compared to the WT mice (Figure 7G, Paper I, Figure 1G).  
 
4.1.1.3 miR-146a regulates the sensitivity of keratinocytes to IL-17A 
As genes regulated by IL-17A were enriched among the deregulated genes in BL6/miR-
146mice as compared to control mice in the imiquimod-induced model, we next 
hypothesized that miR-146a could regulate IL-17A pathway response. To test this, we isolated 
primary keratinocytes from miR-146mice or WT mice and treated them with IL-17A for 6 
hours. We tested the expression of Cxcl1, an IL-17A response gene and a chemoattractant for 
neutrophils, using qRT-PCR. IL-17A induced the expression of Cxcl1 in both WT and miR-
146a-defecient keratinocytes, however the IL-17A-mediated induction of Cxcl1 was 
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significantly higher in miR-146keratinocytes compared to WT keratinocytes, suggesting 
that the deletion of miR-146a increases the keratinocyte sensitivity to IL-17A (Paper I, Figure 
2A). In order to judge the global impact of miR-146a on IL-17 pathway next, GSEA of IL-17A 
regulated genes was performed using deferentially expressed genes upon overexpression of 
miR-146a in normal human primary keratinocytes (Meisgen et al., 2014). GSEA analysis on 
the whole transcriptome revealed a global impact of miR-146a overexpression on IL-17A 
pathway as the genes mediating IL-17A effects were significantly negatively enriched in miR-
146a mimic treated keratinocytes (Paper I, Figure 2B).  
Next we treated human primary keratinocytes with IL-17A in a time course fashion and tested 
the expression of miR-146a and human ortholog of Cxcl1, IL-8 using qRT-PCR. Notably, IL-
17A induced IL-8 expression as early as 3 hours post-treatment with a maximal expression at 
6 hours. IL-17A induced miR-146a expression 6 hours post-treatment. A sudden drop in the 
expression of IL-8 was observed after the miR-146a upregulation suggesting a negative 
regulation of IL-8 by miR-146a (Paper I, Figure 2C). To test this hypothesis in detail we treated 
human primary keratinocytes with different doses of IL-17A upon overexpression or inhibition 
of miR-146a. qRT-PCR and ELISA analysis demonstrated that the overexpression of miR-
146a suppressed the IL-17A-induced expression and secretion of IL-8 (Paper I, Figure 2D). On 
contrary to this, inhibition of endogenous miR-146a levels in keratinocytes enhanced the IL-
17A-induced expression and secretion of IL-8 (Paper I, Figure 2E). EC50 calculation for IL-
17A revealed that miR-146a inhibition significantly doubled the sensitivity of keratinocytes 
towards the cytokine treatment in terms of IL-8 expression (Paper I, Figure E7).  
Studies have shown that IL-17A effects are majorly mediated by phosphorylation and nuclear 
translocation of NF-кB p65 subunit. To test the effects of miR-146a on IL-17A signalling next 
we tested the phosphorylation status of p65 upon IL-17A induction in combination with miR-
146a overexpression or inhibition. As expected, IL-17A strongly induced p65 phosphorylation 
in the cells treated with control oligonucleotide (Paper I, Figure 2F). IL-17A-induced 
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phosphorylation of p65 was decreased upon miR-146a overexpression while miR-146a 
inhibition further enhanced IL-17A-induced phosphorylation of p65 (Paper I, Figure 2F). In 
summary these results point towards an impact of miR-146a on IL-17A mediated effects in 
keratinocytes and suggest a potential role of miR-146a, as a negative feedback regulator of IL-
17 pathway.  
 
4.1.1.4 miR-146a knockout mice present delayed resolution of inflammation 
The Imiquimod-induced mouse model of psoriasis-like inflammation is an acute model and 
mice spontaneously heal after discontinued application of imiquimod. IL-17A has been shown 
to be critical in psoriasis pathogenesis and imiquimod-induced psoriasis-like skin inflammation 
(van der Fits et al., 2009). As we observed a negative regulation of IL-17A pathway by miR-
146a, we hypothesize that the BL6/miR-146mice could have more severe skin inflammation 
and a faulty spontaneous healing. To test this, we applied imiquimod on the shaved back skin 
of BL6/miR-146mice and WT mice for 6 consecutive days and followed the spontaneous 
healing period up to 10 days by observing features of psoriasis-like skin inflammation such as 
erythema, scaling and thickness (Figure 8A, Paper I, Figure 4A).  
Figure 8: (A) Experimental setup. (B-C) Macroscopic image of the imiquimod treated mice 
along with the individual or cumulative scoring for erythema, scaling and skin thickness. 
Reproduced with permission from Srivastava et al., 2016. Copyright Elsevier. 
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Both BL6/miR-146and WT mice developed skin inflammation, however the symptoms of 
psoriasis-like skin inflammation were more severe in BL6/miR-146mice (Figure 8B-C, 
Paper I, Figure 4B-C). Scoring for erythema, scaling and skin thickness showed that the WT 
mice regained the normal skin at the 8th day (Figure 8C, Paper I, Figure 4C). While WT mice 
could completely resolve imiquimod-induced skin inflammation by day 10, miR-146 knockout 
mice still showed persistent signs of inflammation such as erythema, scaling and thickness 
(Figure 8C, Paper I, Figure 4C). In conclusion, BL6/miR-146mice presented a more severe 
inflammation and incomplete spontaneous healing after discontinuing of the imiquimod 
treatment.  
 
4.1.1.5 Local delivery of miR-146a mimics in mice reduces psoriasis-like skin 
inflammation  
Our results pointed towards a protective role of miR-146a in psoriasis. Next we sought to 
investigate the therapeutic potential of miR-146a. To this end miR-146a mimics or scramble 
oligonucleotides were injected to the shaved back skin of the WT mice 1 day prior to the 
imiqimod application, first day and third day imiqimod application using in vivo transfecting 
agent (Figure 9A, Paper I, Figure 5A).  
 
Figure 9: (A) Experimental setup. (B) Skin thickness measured over a course of 4 days of  
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imiquimod treatment. (C)Histology for mice skin and quantification of epidermal thickness. 
(D) Immunohistochemistry for Ki67. Reproduced with permission from Srivastava et al., 2016. 
Copyright Elsevier. 
 
Skin thickness and severity score revealed that mice injected with miR-146a mimics were 
protected against imiquimod-induced psoriasiform skin inflammation compared to the mice 
injected with scramble control (Figure 9B, Paper I, Figure 5B). Histology of skin section 
depicted a thinner epidermis in mice injected with miR-146a mimics compared to the scramble 
injected mice (Figure 9C, Paper I, Figure 5C). In addition, immunohistochemistry 
demonstrated lower number of Ki67 positive keratinocytes in miR-146a mimic injected mice, 
suggesting a protective role of miR-146a (Figure 9D, Paper I, Figure 5D). In conclusion, these 
results suggested that local delivery of miR-146a could alleviate psoriasis-like skin 
inflammation.   
 
4.1.2 Discussion  
Genetic variation among psoriasis patients is critical in disease predisposition (Ray-Jones et 
al., 2016). To date, several psoriasis susceptibility regions have been identified and genetic 
variation in major histocompatibility complex (MHC) class I (HLA-C*06) confers the major 
risk for psoriasis (Ray-Jones et al., 2016). Notably, very little is known about the genetic 
variation among the non-coding RNA leading to psoriasis susceptibility (Pivarcsi et al., 2014). 
The SNP rs2910164 is located in the stem region of the miR-146a precursor and a change from 
G to C in this region result in higher levels of mature miR-146a (Jazdzewski et al., 2008). In 
line with previous studies, our data also demonstrated higher mature levels of miR-146a in 
psoriasis patients with rs2910164-CC genotype than the rs2910164-GG genotype. A protective 
association of rs2910164 to psoriasis was observed in our Swedish psoriasis patient cohort. We 
observed a strong protective association of rs2910164 to psoriasis upon stratification in HLA-
C*06-negative patients and in patients with early onset of the disease. Interestingly, the 
protective C allele of rs2910164 is major allele in Chinese Hans population, where psoriasis 
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incidence rate is less than 1% (Zhang et al., 2014). In this population G allele is minor and 
GG/GC genotype of rs2910164 confer increased risk of psoriasis (Zhang et al., 2014). 
Remarkably, in Caucasian population G allele for rs2910164 is the major allele and psoriasis 
incidence rate is around 3-4% (Naldi, 2004), suggesting a possible protective role of miR-146a 
in psoriasis.  
In accordance with the protective effect of rs2910164, which allows higher expression of 
mature miR-146a, the deletion of miR-146a in mice led to earlier onset of the imiquimod-
induced psoriasiform skin inflammation. An essential hallmark of psoriasis is keratinocyte 
hyper proliferation (Lowes et al., 2014). Notably, deletion of miR-146a in mice led to higher 
number of Ki67 positive keratinocytes in epidermis of miR-146a-deficiant mice which further 
increased upon imiquimod induction, suggesting a role of miR-146a in regulating keratinocytes 
proliferation. A possible mechanism for increased proliferation could be explain by the 
previously identified targets of miR-146a in keratinocytes such as EGFR, FERMT1 and IL-8 
which are important for the positive regulation of cell proliferation (Hermann et al., 2017, 
Rennekampff et al., 2000, Zhang et al., 2014). Imiquimod-induced mouse model of psoriasis 
is an acute model of the disease and mice spontaneously heal upon discontinuation of the 
imiquimod application (van der Fits et al., 2009). However, miR-146a knockout mice presented 
severe inflammation and delayed resolution of the skin inflammation after the discontinuation 
of the imiquimod application. As shown before (van der Fits et al., 2009), WT mice 
spontaneously healed by day 8 of the experiment. Our results demonstrate that the deletion of 
miR-146a in mice prime the skin for inflammatory triggers. Our results showing enhanced skin 
inflammation in miR-146a knockout mice are in line with the previous findings, showing 
spontaneous development of chronic inflammation in aged miR-146a knockout mice 
resembling the autoimmune disease, systemic lupus (Boldin et al., 2011).  
Our results indicated that miR-146a negatively regulated IL-17A response pathway and 
inhibition of miR-146a primed the keratinocytes for inflammation. Functionally, miR-146a 
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regulated neutrophil chemotaxis which could be relevant to psoriasis as neutrophils are present 
in high number in psoriasis. MiR-146a is a strong negative regulator of NF-кB pathway and 
targets multiple genes in this pathway such as TRAF6 and IRAK1 (Meisgen et al., 2014). Our 
results indicated negative regulation of basal and IL-17A-induced p65 phosphorylation and 
inflammatory mediators IL-8 and CCL20 by miR-146a.  
Although miR-146a is overexpressed in psoriasis (Sonkoly et al., 2007), there is still an 
activation of IL-17A/NF-кB axis (Martin et al., 2013). A possible explanation for this 
discrepancy could be explained by the multifactorial aetiology of psoriasis and the anti-
inflammatory effects of miR-146a is simply not enough to completely halt the skin 
inflammation in psoriasis.  
Therapeutically, miR-146a mimic injection in WT mice ameliorates against imiquimod-
induced psoriasiform skin inflammation. In addition, application of miR-146a mimics using 
cell penetrating peptide PepFect6 in mice was successfully shown to deliver the miR-146a 
mimics to the skin leading to negative regulation of NF-кB axis (Urgard et al., 2016). The 
results with the miR-146a delivery with the liposome based injection or PepFect6 in mice 
demonstrated potential anti-inflammatory effects of miR-146a, which is encouraging and could 
be utilize in future to treat psoriasis alone or in combination with other available therapies. 
In summary, our results identified a protective association of miR-146a SNP (rs2910164) to 
psoriasis. Functionally, miR-146a was found to be a potent suppressor of IL-17A-mediated 
skin inflammation. IL-17A induce NF-кB pathway in keratinocytes, leading to upregulation of 
miR-146a (Figure 10). MiR-146a act as a negative feedback regulator of IL-17A/NF-кB axis 
and act as a break on inflammation (Figure 10). 
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Figure 10: Schematic of miR-146a regulation and function.  
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4.2 MIRNA LANDSCAPE OF PSORIATIC KERATINOCYTES 
Communication between keratinocytes and immune cells is an essential element regulating 
psoriasis pathogenesis. Despite being the key structural cells in presenting the hallmarks of 
psoriasis such as acanthosis, parakeratosis, and papillomatosis (Lowes et al., 2014, Perera et 
al., 2012), for several years, keratinocytes were thought to be mere passive bystanders in 
psoriasis. Recent studies demonstrated the ability of keratinocytes to produce antimicrobial 
peptides, cytokines and chemokines to communicate with the immune cells, thus regulating 
psoriasis progression and maintenance (Lowes et al., 2014, Nestle et al., 2009b, Perera et al., 
2012).  
MiRNAs have been implicated in regulating keratinocyte proliferation, differentiation, and 
keratinocyte response to cytokines (Lerman et al., 2011, Meisgen et al., 2014, Srivastava et al., 
2017, Xu et al., 2011, Xu et al., 2013). Studies dissecting the global miRNA signature of 
psoriasis were performed mostly by utilizing full depth skin biopsies (Joyce et al., 2011, 
Sonkoly et al., 2007, Zibert et al., 2010) or in one case laser-dissected psoriasis epidermis 
(Lovendorf et al., 2015) which contains a cellular pool of immune and structural cells from 
epidermis and dermis, thereby masking the cell-specific changes in miRNA landscape. In this 
study, we therefore aimed to identify keratinocyte-specific alterations in miRNA signature of 
psoriasis.  
 
4.2.1 Results  
To this end, skin biopsies were collected from psoriasis lesional as well as non-lesional skin 
(n=9) and healthy donors (n=9). Epidermis was separated from dermis and CD45neg cells 
(predominantly keratinocytes) were negatively sorted from epidermal sheets using magnetic 
MACS MS columns. Total RNA was extracted and small RNA sequencing was performed 
(Paper II, Supplementary Fig. S1). On an average 20 million clean reads were obtained per 
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sample for small RNAs and analysis of the results revealed 411 known and 30 putative novel 
robustly expressed miRNAs. In addition, a 3’ end heterogeneity was observed in the canonical 
miRNAs and isomiRs with 3’ end modification (3’ addition or 3’ deletion) were significantly 
enriched in psoriatic keratinocytes (Paper II, Supplementary Fig. S2). Analysis of small RNA 
sequencing data by EdgeR (Bioconductor) revealed differential expression of 104 miRNAs in 
psoriatic keratinocytes compared to healthy keratinocytes (Figure 11a-c, Paper II Figure 1a-c).  
 
Figure 11: a) miRNA signature of psoriatic keratinocytes compared to healthy keratinocytes 
(FC > 1.4; FDR < 0.1). (b-c) List of top 30 up and downregulated miRNAs based on fold 
change.  
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In addition, expression of 87 miRNAs were altered in psoriasis lesional keratinocytes compared 
to non-lesional keratinocytes (Paper II, Supplementary Fig. S3a). Interestingly, 7 miRNAs 
were differentially expressed in keratinocytes sorted from non-lesional psoriasis skin compared 
to normal keratinocytes, suggesting preclinical intrinsic changes in miRNA signature (Paper 
II, Supplementary Table. S3). Our analysis also identified few miRNAs whose expression 
could be altered in psoriatic keratinocytes due to the genetic variation in psoriasis (Paper II, 
Supplementary Table S7). 
Strikingly, we identified several miRNAs (32 up-regulated and 18 down-regulated miRNAs in 
the PP vs H comparison and 36 upregulated and 18 downregulated miRNAs in the PP vs. PN 
comparison), which have not been identified by the previous studies using full-depth biopsies 
(Joyce et al., 2011, Sonkoly et al., 2007, Zibert et al., 2010) or micro-dissected epidermis  
(Lovendorf et al., 2015) (Paper II, Supplementary Figure 5a-d, Supplementary Table S4-S5).  
Next we selected two upregulated miRNAs (miR-941 and miR-1307-3p) for validation with 
qRT-PCR in an extended validation cohort (H=19, Psoriasis (PP=19; PN=19). Human-specific 
miR-941 was found upregulated in psoriatic keratinocytes and was not identified by any earlier 
global miRNAs profiling studies in psoriasis. MiR-1307-3p was also found to be upregulated 
in psoriatic keratinocytes and was not characterized before. qRT-PCR analysis confirmed 
upregulation of both the miRNAs in psoriatic keratinocytes compared to normal keratinocytes 
(Paper II, Figure 2a-b).   
 
4.2.2 Discussion  
In the past, several studies have explored the miRNome of psoriasis by using either small RNA 
sequencing or microarray and reported altered expression of miRNAs in the lesional skin 
(Joyce et al., 2011, Lovendorf et al., 2015, Sonkoly et al., 2007, Zibert et al., 2010). Apart from 
identifying known signature of miRNAs in psoriasis such as miR-21, miR-31, miR-146a, miR-
 54 
125b and miR-99a (Meisgen et al., 2014, Meisgen et al., 2012, Srivastava et al., 2017, Xu et 
al., 2011, Xu et al., 2013) our results identified a large number of keratinocyte-specific 
alteration in miRNAs expression which were not identified by previous studies. A possible 
explanation for this could be the use of full depth skin or epidermis which contains a mix of 
different cell types such as keratinocytes, immune cells, melanocytes and fibroblast. The 
abundance of miRNAs may be different in these cell types and keratinocyte-specific changes 
in miRNAs expression can be compensated by increased expression in other cell types, or 
increased proportion of other cell types expressing the miRNA.  
A small part of deregulated miRNA expression in psoriatic keratinocytes can be explained by 
their genomic location which coincided in the proximity of genetic variation in psoriasis. The 
altered expression of these miRNAs could be due the presence of lead SNP in an enhancer or 
silencer regions which could regulate the miRNA expression (Tsoi et al., 2017). Rest of the 
changes in miRNA expression may be explained either by epigenetic regulation or the 
inflammatory cytokine milieu of psoriasis.  
In conclusion, our study dissected the miRNA landscape of keratinocytes in psoriasis, which 
could serve as platform for future functional studies exploring the role of miRNAs in psoriasis. 
Genetic variation could contribute to some of the changes in miRNA expression. In addition 
we also validated the expression of the human-specific miRNA-miR-941 and miR-1307-3p 
using qRT-PCR which could mediate keratinocyte response in psoriasis. Overall, our results 
may provide an insight for the future research targeting keratinocytes-specific miRNA changes 
for developing topical therapies. 
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4.3 MIR-149 REGULATES THE JAK-STAT PATHWAY IN KERATINOCYTES  
We identified miR-149 as one of the downregulated miRNA in sorted keratinocytes from 
psoriasis lesions compared to keratinocytes isolated from healthy donors in paper II. In this 
study (paper III), we investigated the role of miR-149 in psoriasis pathogenesis.   
 
4.3.1 Results  
4.3.1.1 MiR-149 is downregulated in psoriasis  
Our small RNA sequencing analysis identified downregulation in the expression of miR-149 
in keratinocyte in psoriasis (Paper II Figure 1a, Supplementary Table S5b, and Figure 12a, 
Paper III Figure 1a). The downregulation of miR-149 was further validated by qRT-PCR in an 
extended cohort of sorted keratinocytes from psoriasis (L = 20, NL = 20) and healthy skin (H 
= 19) (Figure 12b, Paper III Figure 1b). The localization of miR-149 in epidermal compartment 
and downregulation in psoriasis lesions were further confirmed with LNA-based in situ 
hybridization (Figure 12c, Paper III Figure 1c).  
 
Figure 12: (a) Normalized read count of miR-149 in small RNA sequencing. (b) Expression 
analysis of miR-149 by qRT-PCR. (c) In situ hybridization for miR-149 in healthy and psoriasis 
skin.  
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4.3.1.2 IFN-γ suppresses miR-149 expression via the JAK/STAT-signalling 
pathway 
Next to detect possible factors contributing to the altered expression of miR-149 in psoriasis, 
we treated human primary keratinocytes with psoriasis associated cytokines such as IFN-γ, IL-
1β, IL-17A, IL-22, TNF-α, IL-36α or a combination of IL-17A+IL-22+TNFα. INF-γ but not 
the other tested cytokines regulated miR-149 expression. IFN-γ significantly downregulated 
miR-149 expression at 24, 48, 72 and 96 hours after treatment (Paper III Figure 2a, 
Supplementary Figure S1). Next, to test if the downregulation of miR-149 is transcriptional or 
posttranscriptional modulation by IFN-γ in keratinocytes, we detected the expression of 
primary transcript of miR-149 (pri-miR-149) in a time course manner. Notably, pri-miR-149 
was downregulated as early as 1 hour after IFN-γ treatment, suggesting a transcriptional effect 
of IFN-γ on miR-149 expression (Paper III Figure 2b).  
In parallel, known IFN-γ-inducible genes, CXCL9, 10, 11 and IL-6 were induced as early as 1 
to 3 hours after IFN-γ treatment in monolayer keratinocytes and maximal expression of these 
inflammatory mediators was observed at 24 hours. Thus, miR-149 downregulation by IFN-γ 
at 24 hours coincided with the maximal expression of CXCL9, 10, 11 and IL-6 (Paper III Figure 
2a-b) suggesting that miR-149 may regulate inflammatory pathways downstream of IFN-γ. 
Moreover, IFN-γ was also able to downregulate miR-149 expression in 3D epidermal 
equivalents at 72 hours suggesting that effects of IFN-γ on miR-149 expression is not just 
limited to monolayer culture of keratinocytes (Paper III Figure 3b).  
Keratinocytes expresses IFN-γ receptor, which upon binding to IFN-γ activates JAK/STAT 
signalling via JAK1 and JAK2 leading to the phosphorylation of STAT1. Next we tested 
whether blocking of JAK proteins can rescue IFN-γ-suppressed miR-149 expression. To this 
end, human primary keratinocytes were pre-treated with ruxolitinib (JAK1 and JAK2 inhibitor) 
or tofacitinib (JAK1 and JAK3 inhibitor) for 1 hour, prior to IFN-γ treatment. Both ruxolitinib 
and tofacitinib rescued IFN-γ-suppressed miR-149 expression (Paper III Figure 4a). 
  57 
Remarkably, treatment with both of these inhibitors in the absence of any other treatment could 
increase the expression of miR-149, suggesting a slight suppressive effect by JAKs on miR-
149 expression in resting keratinocytes (Paper III Figure 4a). Altogether these results 
demonstrate that IFN-γ downregulates miR-149 expression by modulating JAK-STAT axis.  
 
4.3.1.3 miR-149 regulates genes in JAK/STAT signalling pathway  
Next, we aimed to test the effects of miR-149 on keratinocyte transcriptome. To do so, we 
inhibited endogenous miR-149 by transfecting miR-149 inhibitor in keratinocytes. Microarray 
analysis for whole transcriptome revealed that miR-149 inhibition had a robust effect on gene 
expression as 1164 genes (446 upregulated and 718 downregulated) were differentially 
expressed (Benjamini & Hochberg, P < 0.05, FCH > 1.4) compared to control oligonucleotides 
(Paper III Figure 5a). Interestingly, genes involved in JAK-STAT signalling pathway, MAPK 
signalling pathway, cytokine-cytokine receptor interaction, response to interferon-gamma and 
positive regulation of JAK-STAT cascade were enriched among the upregulated genes upon 
miR-149 inhibition in keratinocytes (Paper III Figure 5b-c). Our results indicate that miR-149 
negatively regulates the JAK/STAT pathway in resting keratinocytes.  
 
4.3.1.4 miR-149 potentiates IFN-γ responses  
Next we analysed the effect of miR-149 on the keratinocyte transcriptome under inflammatory 
conditions in IFN-γ-treated keratinocytes. IFN-γ had a strong effect on the keratinocyte 
transcriptome and 4119 genes were found to be differentially expressed (Benjamini & 
Hochberg, P < 0.05, FCH > 1.4) (Paper III Supplementary Figure S2a). In order to explore the 
effects of miR-149 on keratinocyte responses towards IFN-γ, we analysed the transcriptome of 
keratinocytes where endogenous miR-149 was inhibited and cells were further stimulated with 
IFN-γ. Interestingly, miR-149 inhibition in IFN-γ-treated keratinocytes led to differential 
expression of 1077 genes compared to IFN-γ-treated keratinocytes transfected with control 
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oligonucleotide (Benjamini & Hochberg, P < 0.05, FCH > 1.4) (Paper III Supplementary 
Figure S3a).  
 
Figure 13: (a-b) IFN-γ-induced and suppressed genes whose expression was further 
potentiated upon miR-149 inhibition. (c-d) KEGG pathway and biological processes enriched 
among these genes.    
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Remarkably, miR-149 inhibition potentiated IFN-γ responses in keratinocytes and 126 IFN-γ-
suppressed genes were further suppressed and 103 IFN-γ-induced genes were further induced 
upon miR-149 inhibition in keratinocytes (Figure 13a-b, Paper III Figure 6a-b). Strikingly, 
miR-149 strongly affected the genes regulating IFN-γ/JAK/STAT axis such as STAT1, 
STAT5A, SOCS3, IL20, IL23A, IL10RB, IL20RB, CCL5, CCL2 and CXCL16, indicating that  
miR-149 negatively regulates IFN-γ-induced inflammatory pathways (Figure 13c-d, Paper III, 
Figure 6c-d). 
 
4.3.2 Discussion  
Our results point to a negative regulation of IFN-γ/JAK/STAT axis in keratinocytes by miR-
149. MiR-149 was identified as one of the downregulated miRNAs in psoriatic keratinocytes 
compared to normal keratinocytes. Decreased expression of miR-149 was not identified in 
previous studies profiling the miRNA signature of psoriasis. This could be due the fact that we 
analysed the landscape of miRNAs of sorted psoriatic keratinocytes while other studies have 
used mixture of cellular pool obtained from full depth skin biopsies (Joyce et al., 2011, Sonkoly 
et al., 2007, Zibert et al., 2010). Downregulation of miR-149 in psoriatic keratinocytes was 
further validated in an extend validation cohort using qRT-PCR. Functionally, miR-149 has 
been previously implicated in inflammation, apoptosis, proliferation, cancer metastasis and 
chemo-resistance (Chen et al., 2018, He et al., 2018, She et al., 2014, Tian and Yan, 2016, 
Wang et al., 2012, Xu et al., 2014). Our findings suggest an anti-inflammatory role of miR-149 
in psoriasis which is in line with previous studies showing anti-inflammatory role of this 
miRNA in macrophages and osteoarthritis (Chen et al., 2018, Xu et al., 2014). 
Among tested psoriasis-associated cytokines only IFN-γ was able to regulate miR-149 
expression in human primary keratinocytes. IFN-γ is involved in psoriasis pathogenesis and 
mRNA expression of this cytokine has been shown to be upregulated in psoriasis skin along 
with increased levels of IFN-γ in serum of psoriasis patients (Harden et al., 2015, Johnson-
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Huang et al., 2012, Nestle et al., 2009b, Perera et al., 2012). Single treatment of IFN-γ in human 
primary keratinocytes resulted in rapid transcriptional decrease of primary transcript of miR-
149 at 1 hour and a strong suppression of mature miR-149 was observed at 24 hour which 
remained suppressed even 4 day after IFN-γ treatment. These results indicate that upregulated 
IFN-γ levels in psoriasis skin (Johnson-Huang et al., 2012, Nestle et al., 2009b, Perera et al., 
2012) could at least in part be responsible for miR-149 downregulation.  
Mechanistically, IFN-γ-induced JAK/STAT axis was important in regulating miR-149 
expression as inhibition of JAKs rescued IFN-γ-suppressed miR-149 expression. Inhibition of 
JAKs in resting keratinocytes, induced miR-149 expression, suggesting JAK/STAT axis act as 
a block on miR-149 expression even is homeostatic condition.  
Transcriptomic analysis upon miR-149 inhibition in resting keratinocyte revealed that miR-
149 may act as a break on inflammatory mediators as the genes regulating immune-related 
functions and biological pathways such as JAK-STAT signalling were significantly 
upregulated. Remarkably, 57% of these upregulated genes were IFN-γ-inducible genes and 
53% of downregulated genes were IFN-γ-suppressed genes. These results hint towards a global 
impact of miR-149 on IFN-γ/JAK/STAT pathway in homeostatic conditions.  
Notably, inhibition of miR-149 in IFN-γ-treated keratinocytes further potentiated IFN-γ 
responses and the expression of JAK-STAT signalling pathway genes such as STAT1, 
STAT5A, SOCS3, IL20, IL23A, IL10RB, IL20RB, CCL5, CCL2 and CXCL16 were further 
induced in these cells. Our results suggest that miR-149 may negatively regulate IFN-
γ/JAK/STAT axis by targeting one or more regulators of this pathway.   
JAK/STAT signalling is active in psoriasis (Hald et al., 2013) and has been targeted by JAK 
inhibitors such as tofacitinib (JAK1/3), ruxolitinib (JAK1/2) and baricitinib (JAK1/2) 
(Palanivel et al., 2014, Welsch et al., 2017). Recently, a study demonstrated that STAT1 mRNA 
is upregulated and both the phosphorylation sites of STAT1 (p-STAT1-Tyr701 and p-STAT1-
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Ser727) are phosphorylated in psoriasis skin lesions (Hald et al., 2013). STAT1 is key 
transcription factor in regulating IFN-γ responses by binding to the interferon gamma activated 
sequence (GAS) promoter element to induce expression of inflammatory mediators such as 
CXCL9, 10, 11 and IL-6 (Kanda et al., 2007, Ramana et al., 2002). CXCL 9, 10, 11 and IL-6 
are also present in high levels in psoriasis skin and are involved in either TH1 cell chemotaxis 
or inflammation (Nedoszytko et al., 2014, Turner et al., 2014). ELISA and qRT-PCR analysis 
showed that miR-149 negatively regulated the secretion and expression of basal as well as IFN-
γ-induced IL-6 in keratinocytes. IL-6 has been shown to be a direct target of miR-149 in other 
cell type (Li et al., 2015). In addition, to IL-6 which has been shown to be direct target, other 
IFN-γ-response genes (CXCL 9, 10, 11) were regulated by miR-149, suggesting that one or 
more mediators of this pathway are targeted by miR-149.These results further provide evidence 
for negative regulation of keratinocytes response to IFN-γ by miR-149. 
In conclusion, our results indicate an anti-inflammatory role of miR-149 in psoriasis 
specifically in the context of JAK/STAT signalling. Downregulation of miR-149 in psoriatic 
keratinocytes could lead to activation of JAK/STAT signalling pathway leading to the chronic 
inflammation. To exert its anti-inflammatory function it is plausible that miR-149 targets one 
or more elements of the IFN-γ/JAK1-2/STAT1 pathway. 
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4.4 EFFECTS OF TOFACITINIB ON KERATINOCYTE TRANSCRIPTOME  
In recent years, JAK inhibitors gained popularity as an immunomodulatory drug to treat a 
variety of diseases such as psoriasis, atopic dermatitis, alopecia areata and vitiligo (Palanivel 
et al., 2014, Welsch et al., 2017). Tofacitinib targets JAK1 and JAK3 and to a lesser extent to 
JAK2 and Tyk2. Therapeutically, tofacitinib has been shown efficacious in treating psoriasis 
in oral and topical formulations (phase III and phase II trials) (Palanivel et al., 2014, Welsch et 
al., 2017). Effects of tofacitinib were thought to be mediated by T cells, however evidence 
suggest that STAT3 pathway is also active in keratinocytes (Hsu and Armstrong, 2014). In this 
study we aimed to investigate if the targets of tofacitinib are expressed by keratinocytes and 
the possible effects of tofacitinib on keratinocytes transcriptome.   
 
4.4.1 Results 
4.4.1.1 Keratinocytes expresses JAK proteins 
First to test that whether the targets of tofacitinib- JAKs (JAK1, JAK2, JAK3 and Tyk2) are 
expressed by keratinocytes we performed qRT-PCR analysis for JAK1, JAK2, JAK3 and Tyk2 
in comparison to PBMCs. Expression analysis verified that the JAK1 JAK2 and Tyk2 were 
expressed by keratinocytes and their expression was comparable to PBMCs, while JAK3 was 
expressed at a lower level (Paper IV, Figure 1a). Western blot analysis for JAK1, JAK2 and 
JAK3 using cell lysate from cultured human primary keratinocytes also confirmed their protein 
expression in keratinocytes (Paper IV, Figure 1b).  
 
4.4.1.2 Tofacitinib inhibits JAK-STAT signalling in keratinocytes  
Next we tested whether tofacitinib can inhibit JAK-STAT signalling in keratinocytes. To this 
end, keratinocytes were pre-treated with different dose of tofacitinib or vehicle control DMSO 
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followed by treatment with IL-22, a known activator of JAK-STAT signalling. qRT-PCR 
analysis of downstream genes of IL-22/STAT3 signalling- S100A8 and S100A9 verified that 
the pre-treatment with all the tested doses of tofacitinib were able to block IL-22 induced 
expression of S100A8 and S100A9 in keratinocytes (Paper IV, Figure 2a-b). Moreover, 
western blot analysis of p-STAT3 (Tyr705 and Ser727) and p-STAT1 further confirmed that 
tofacitinib prevented the IL-22 induced phosphorylation of STAT3 and STAT1 leading to 
inhibition of JAK-STAT axis in keratinocytes (Paper IV, Figure 3a-c).  
 
4.4.1.3 Tofacitinib prevents IL-22 induced gene expression changes  
In order to observe effects of tofacitinib on the keratinocyte transcriptome, we performed whole 
transcriptome analysis using microarray. A single treatment of IL-22 in keratinocytes resulted 
in the differential expression 898 genes at 6 hour after the treatment. Strikingly, 93% of the Il-
22-regulated gene expression changes were partially prevented by pre-treatment with 
tofacitinib. Out of these differentially expressed genes 193 genes were significantly 
differentially expressed by both IL-22 vs untreated keratinocytes and tofacitinib pre-treated + 
IL-22 treated vs IL-22 treated keratinocytes (Figure 14a, Paper IV, Figure 4a). Interestingly, 
all the IL-22-regulated genes were regulated in opposite direction by tofacitinib pre-treatment 
(Figure 14a, Paper IV, Figure 4a). Network analysis among these differentially expressed 
genes further confirmed a direct effect of tofacitinib on JAK-STAT axis in keratinocytes as the 
genes regulating JAK-STAT pathway along with T-cell activation, endothelial and epidermal 
cell differentiation were clustered together (Figure 14b, Paper IV, Figure 4b). Moreover, 
psoriasis- associated biological processes such as keratinocyte differentiation and response to 
cytokines were significantly enriched among the differentially expressed genes (data not 
shown). The enriched biological processes among tofacitinib regulated genes corresponds to 
the known IL-22 functions in psoriasis such as inhibition of terminal differentiation of 
 64 
keratinocytes and regulation of keratinocyte proliferation and suggest that tofacitinib could 
prevent these IL-22-induced effects.          
 
Figure 14:  (a) IL-22- regulated genes which were regulated by tofacitinib in opposite 
direction. (b) Network analysis among differentially expressed genes. Reproduced with 
permission from Srivastava et al., 2018. Copyright Acta Dermato-Venereologica. 
 
Next we validated the expression of two IL-22-regulated genes S100A7 and EGR1 which were 
regulated by tofacitinib in opposite direction. S100A7 (psoriasin) is a psoriasis associated 
antimicrobial peptide which is upregulated in psoriasis and regulates keratinocytes proliferation 
and differentiation. EGR1 is a transcription factor regulating cell growth, differentiation and 
survival. Expression analysis using qRT-PCR confirmed upregulation of S100A7 and 
downregulation of EGR1 by IL-22 in keratinocytes and regulated by tofacitinib in opposite 
direction (Figure 15a-b, Paper IV, Figure 5a-b). These results indicate that tofacitinib could 
reverse IL-22 effects in keratinocytes.  
Next, to verify the relevance of these findings in psoriasis we analysed the expression of 
S100A7 and EGR1 by qRT-PCR in CD45neg cells (predominantly keratinocytes) isolated from 
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healthy and psoriasis (lesional and non-lesional) skin. Expression of S100A7 was found 
upregulated in psoriatic keratinocytes, which is in line with our results and previous findings 
(Figure 15c, Paper IV, Figure 5c). On contrary, EGR1 was downregulated in psoriatic 
keratinocytes compared to keratinocytes isolated from healthy donors (Figure 15d, Paper IV, 
Figure 5d).  
 
Figure 15: (a-b) Expression of S100A7 and EGR1 in keratinocytes upon IL-22 or tofacitinib 
treatment. (c-d) Expression of S100A7 and EGR1 in keratinocytes sorted from healthy or 
psoriasis (lesional and non-lesional) skin. . Reproduced with permission from Srivastava et al., 
2018. Copyright Acta Dermato-Venereologica. 
 
4.4.2 Discussion  
Altogether, our results show that tofacitinib have direct effects on keratinocytes transcriptome 
and can reverse IL-22-mediated gene expression changes by modulating JAK-STAT axis. 
These results imply that the effects of tofacitinib are not limited only to T-cells but can also be 
mediated by keratinocytes. JAK-STAT axis is important in psoriasis, as evidenced by the 
genetic association of STAT3 and Tyk2 with psoriasis (Tsoi et al., 2012), the role of STAT3 
in regulating cytokine (IL-6, IL-10, IL-20 and IL-22) signalling and TH17 cell differentiation 
(Miyoshi et al., 2011, Sestito et al., 2011). In addition, keratinocyte-specific constitutive 
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activation of STAT3 in mice resulted in spontaneous development of psoriasis-like skin 
inflammation (Sano et al., 2005).  
Targeting JAK-STAT axis in keratinocytes could partially explain the effect of topical 
tofacitinib treatment in a phase II randomized clinical trial of psoriasis and atopic dermatitis 
patients (Bissonnette et al., 2016).Our findings are in line with a recent study showing a robust 
reduction in the keratinocyte-meditated transcriptomic changes in lesional skin of psoriasis 
patients treated with oral tofacitinib (Krueger et al., 2016). Our findings support a mode of 
action where tofacitinib could target both keratinocytes and T-cells, which could be relevant 
for both topical and oral formulations. 
In summary, tofacitinib blocks the IL-22-mediated JAK-STAT signalling by targeting JAK1 
and Tyk2 (Figure 16) in keratinocytes and reverses IL-22 mediated transcriptomic changes. In 
the context of psoriasis this mechanism could prevent epidermal hyperplasia and papilomatosis 
induced by IL-22 (Figure 16).  
 
Figure 16: Schematic of mode of action of tofacitinib in keratinocytes. 
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5 CONCLUSIONS 
 
Communication of keratinocytes with trafficking immune cells and skin resident cells has been 
shown to be critical in psoriasis. Cytokine and chemokine networks shape this crosstalk and 
regulate inflammatory pathways in psoriasis. In particular, keratinocyte-derived inflammatory 
mediators and chemokine attract trafficking immune cells and induce cellular inflammation to 
maintain auto loop of inflammation. The objective of this thesis is to uncover the functional 
and regulatory role of miRNAs in regulating keratinocytes response to different cytokines in 
psoriasis.  
In paper I, we show a protective association of miR-146a (rs2910164-CC genotype) to earlier 
onset of psoriasis in HLA-C*06-negative patients. In addition, miR-146 was found to be a 
potent suppressor of IL-17A-mediated skin inflammation and negatively regulated the 
inflammatory mediators, such as IL-8 and CCL20. In line with our findings in human 
keratinocytes, an earlier onset of imiqimod-induced psoriasiform skin inflammation was 
observed in miR-146a knockout mice compared to WT mice. Interestingly lack of miR-146a 
inhibited spontaneous resolution of the psoriasis-like skin inflammation. Remarkably, miR-
146a was also found to have therapeutic potential as injection with miR-146a alleviates 
psoriasis-like skin inflammation in mice. Future studies may target the therapeutic potential of 
miR-146a in resolving skin inflammation in psoriasis.   
In Paper II we identify keratinocyte-specific alterations in miRNA expression in psoriasis. 
Here, we show several yet not identified and characterized miRNAs in psoriasis whose 
expression was altered in a keratinocyte. Deregulated expression of human-specific miR-941 
was validated with qRT-PCR along with miR-1307-3p. This study provide a platform for future 
studies focusing to characterize the functional role of miRNAs in psoriasis.  
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In paper III we expanded our observation from paper II. We identified miR-149 as a 
downregulated miRNA in psoriatic keratinocytes. Our in vitro regulation experiment hinted 
that the high levels of IFN-γ in psoriasis could partially contribute to the downregulation of 
miR-149. JAK/STAT axis was pivotal in regulating miR-149 expression in response to IFN-γ 
as well as in resting keratinocytes. Functionally, miR-149 negatively regulated the JAK/STAT 
pathway and inflammatory mediators such as CXCL9, 10, 11 and IL-6. These results suggest 
that downregulation of miR-149 in psoriatic keratinocytes could potentiate IFN-γ-mediated 
responses in psoriasis. These results would be further corroborated by establishing the 
mechanism of negative regulation of inflammation by miR-149. In addition animal models of 
psoriasis would be utilized to verify the functional role of miR-149 (injection of miR-149 
mimic and inhibitor) in regulating psoriasis pathogenesis in vivo.  
Paper IV identified a new mechanism of the immunomodulatory JAK inhibitor- tofacitinib. 
Here, we show that keratinocytes express the potential targets of tofacitinib and that 
JAK/STAT signalling was suppressed by tofacitinib in keratinocytes. Molecularly, tofacitinb 
has a direct and robust effect on keratinocyte transcriptome and rescued the IL-22-regulated 
transcriptomic changes. This mechanism could in part be responsible for the success of topical 
tofacitinib formulations in psoriasis and atopic dermatitis.  
Altogether, we have explored the function of two miRNAs, miR-146a and miR-149, in 
regulating cytokine signalling in psoriasis. In addition, we also described the keratinocyte-
specific changes in miRNAs expression in psoriasis. Finally, we outlined that tofacitinib may 
also target keratinocytes to mediate its effect in treating psoriasis. In conclusion, this thesis 
highlighted the functional role of miRNAs in shaping the cytokine response in keratinocytes 
and investigated their potential role in psoriasis pathogenesis, progression and maintenance. 
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"Whatever deity may guide my life, dear lord don't let me die tonight. 
But if I shall before I wake, I'd accept my fate." 
“Jay-Z” 
 
